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The study of cell-to-cell signaling peptides contributes to the fundamental understanding 
of physiological processes and improves the effectiveness of pharmaceutical drugs. While 
protein synthesis in animals is stereospecific for all L-form amino acids, a unique and bioactive 
group of D-amino acid-containing peptides (DAACPs) have been found to exist in a broad array 
of animals. DAACPs result from a post-translational modification (PTM) in which an L-amino 
acid residue is enzymatically converted into a D-amino acid residue in the peptide chain. 
Isomerization leads to important changes in the three-dimensional structure and bioactivity of the 
DAACP and increases its resistance to degradation by peptidases.  
However, current research into peptide isomerization is limited because this PTM is not 
easily detected in mass spectrometry-based peptidomics experiments due to the lack of an 
associated mass shift. To address this challenge, we have developed a method for the non-
targeted detection of DAACPs in biological samples and used it to explore the prevalence of 
DAACPs in the neurobiological model organism Aplysia californica. Two novel DAACPs were 
discovered using this method.  
Based on these results, it was hypothesized that an L/D-peptide isomerase exists in 
Aplysia which is responsible for the biosynthesis of DAACPs. An assay for isomerase activity 
was developed and used to partially purify and characterize an L/D-isomerase in the Aplysia 
central nervous system. Furthermore, isomerase activity was detected in multiple tissues in the 
rat, and a mammalian neuropeptide was found to be isomerized by this activity. These findings 
advance our understanding of the extent and function of enzymatic L/D-peptide isomerization as 
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Biologically active peptides are broadly distributed and utilized by plant, bacterial, fungal, and 
animal systems; these peptides play a crucial role in many physiological processes including 
neurotransmission, hormonal regulation, immune responses, and antibiotic actions [1]. For gene-
encoded peptides that are translated as larger protein precursors, the cleavage and post-
translational modification processes are essential for peptide function and regulation. There are 
many instances where differential processing of the precursor protein gives rise to bioactive 
peptides with different functions and localization. A well-known example is the 
proopiomelanocortin (POMC) precursor, which is differentially cleaved in a tissue-specific 
manner by different enzymes. Enzymatic post-translational modifications (PTMs) also 
significantly affect the bioactivity and stability of a peptide. In the case of the POMC-derived 
peptides, acetylation enhances the activity of melanocyte-stimulating hormone (α-MSH) but 
abolishes the activity of β-endorphin [2]. These findings showcase the importance of identifying 
the PTMs of a peptide as well as understanding the distribution and specificity of the enzymes 
that are involved in peptide processing.  
Enzymatic L/D-peptide isomerization is a PTM that has been found in diverse animal species 
from invertebrates to amphibians and monotremes. The D-amino acid-containing peptides 
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(DAACPs) that result from this modification act as neuropeptides, hormones, and toxins that can 
have a much higher potency and stability than the un-modified all-L-form peptides [3-5]. 
However, the prevalence and physiological actions of this PTM in animals has not been well-
studied, and the chirality of amino acid residues in a peptide is not assessed in routine peptide 
discovery and characterization studies in mammalian models.  
Although a number of analytical approaches have been developed for differentiating between L-
form and D-form peptide isomers based on techniques such as tandem mass spectrometry, 
capillary electrophoresis, ion mobility spectrometry and others [5,6], these methods often require 
specific optimization of experimental conditions for a particular peptide of interest. 
Consequently, these methods are useful for confirming the chirality of a potential DAACP, but 
they are less efficient at identifying new DAACP candidates without prior knowledge. Therefore, 
we developed a non-targeted method for the screening of DAACPs in complex biological 
samples. We take advantage of the properties conferred by L-to-D peptide isomerization, 
especially the DAACP’s increased resistance to peptidases, to build a series of assays that is able 
to distinguish a DAACP. This method can be applied to the characterization of DAACPs in 
multiple animal models. 
While over 30 naturally-occurring DAACPs have been discovered in animals, only three 
isomerase enzymes that catalyze L/D-peptide isomerization in animal venom and skin peptides 
have been purified and partially characterized [7]. Although the presence of L/D-peptide 
isomerases in the nervous and endocrine systems can be inferred based on the existence of D-
amino acid-containing neuropeptides and hormones, none of these enzymes have been identified 
to date. A major focus of this work is on studying the neuronal L/D-peptide isomerases, first in 
the model animal Aplysia californica and then in rodents.  
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Aplysia californica is a marine mollusk that is an excellent model for neurobiology research 
because its nervous system is relatively simple and easily accessible. In addition, many of its 
large neurons have well-defined functions and can be uniquely identified based on location and 
morphology [8,9]. Since neurochemistry is well-conserved across animal phyla, some ancient 
neuropeptide families (insulin, FMRFamide, etc.) are found in both Aplysia and mammalian 
systems [10-12]. In this work, Aplysia was selected as an animal model for studying L/D-peptide 
isomerization because DAACPs have already been discovered in its nervous system [13-15]. 
Although enzymatically formed DAACPs in rodent systems have not been confirmed, there is 
evidence for their existence [16-20]. Therefore, methods developed in Aplysia were next applied 
to investigating enzymatic L/D-peptide isomerization in tissues of the mouse and rat.   
 
1.2 Dissertation overview 
Chapter 2 provides a background into L/D-peptide isomerization as a post-translational 
modification in animals.  An overview of known DAACPs and their properties are discussed. 
Studies on the L/D-peptide isomerase enzymes that catalyze the formation of DAACPs are also 
reviewed. Currently, three isomerases have been isolated and partially characterized from the 
spider venom, frog skin secretions, and platypus venom gland extracts. Isomerase activity has 
been detected in the venom of the echidna, which is a member of the monotreme order like the 
platypus. More interestingly, a low amount of isomerase activity was detected in the mouse heart 
[16], but the sequence, substrate, distribution, or mechanism of the mouse isomerase have not 
been studied in detail.  
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Chapter 3 reports on the non-targeted method we developed for identifying novel DAACPs in 
complex biological peptides. In this method, aminopeptidase M is used to screen biological 
peptide mixtures to identify degradation-resistant peptides since DAACPs with a D-amino acid 
residue near the N-terminus are known to resist this enzyme. DAACP candidates are then 
isolated and hydrolyzed, and the chirality of their component amino acids is analyzed using 
liquid chromatography coupled to mass spectrometry (LC-MS). The endogenous peptide is then 
compared to synthetic standards using LC-MS for sequence confirmation. This method was 
applied to screening for DAACPs in Aplysia californica, and two novel D-amino acid-containing 
neuropeptides were identified.  
Chapter 4 introduces an assay for L/D-peptide isomerase activity in Aplysia californica. The 
existence of an Aplysia isomerase is presumed because DAACPs are present in the peptidome, 
but this enzyme has not been isolated or characterized. Assays based on two techniques (matrix-
assisted laser desorption ionization time-of-flight tandem mass spectrometry, or MALDI-TOF 
MS/MS, and liquid chromatography-tandem mass spectrometry in the multiple reaction 
monitoring mode, or LC-MS/MS-MRM) were established, and L-to-D conversion of peptides 
incubated with tissue extracts was successfully detected using both methods.  
Chapter 5 describes the partial characterization of the isomerase activity in Aplysia. Isomerase 
activity was found in central nervous system tissues but not in peripheral tissues, and an acidic 
pH optimum was observed, both of which support the hypothesis that this is a neuropeptide 
processing enzyme. Isomerization was found to proceed in both the L-to-D and D-to-L direction, 




Chapter 6 outlines the methods and experiments that were carried out in an effort to determine 
the protein sequence of the Aplysia isomerase. Activity-guided enzyme purification was 
performed using a combination of protein chromatography techniques, and active isomerase 
fractions were subjected to LC-MS/MS analysis for protein identification. In another approach, 
RNA sequencing was performed on a DAACP-expressing cell type and a control cell type to 
obtain a list of genes that were up-regulated in DAACP-expressing cells. Protein candidates for 
the isomerase were identified on the basis of both LC-MS/MS protein data and gene expression 
data. These protein candidates will be expressed and tested for isomerase activity to confirm the 
sequence of the Aplysia L/D-peptide isomerase.  
Chapter 7 presents the detection and initial characterization of an L/D-peptide isomerase activity 
in the rat. In a study by Koh et al. in 2010 [16], a small amount of isomerase activity was 
observed in the mouse heart, but no follow-up studies on L/D-peptide isomerases in rodents or 
other mammals have been reported since. Using an isomerase assay and enzyme isolation 
protocol adapted from our Aplysia work, we first confirmed isomerase activity in the mouse 
heart and went on to show that isomerase activity is present in multiple tissues in the rat. 
Furthermore, the mammalian neuropeptide FF was found to be a good substrate for the 
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L/D-PEPTIDE ISOMERIZATION IN ANIMALS 
 
 
2.1 L/D-peptide isomerization as a post-translation modification in animals 
Bioactive peptides act as cell-to-cell signaling molecules in the regulation of various 
physiological processes including growth, metabolism, homeostasis, reproduction, and aging [1]. 
Signaling peptides are derived from larger precursor molecules made via ribosomal synthesis, 
and many of these peptides undergo post-translational modifications (PTMs) that are crucial for 
their bioactivity. For example, N-glycosylation of the thyroid-stimulating hormone is required 
for subunit dimerization, which enables receptor binding and hormonal activity. Acetylation of 
α-melanocyte-stimulating hormone confers stability and leads to increased potency, and tyrosine 
sulfation of cholecystokinin 8 introduces a hydrophilic group onto the peptide that affects 
receptor activation [1]. PTMs are important to understand because of their significant impact on 
the function and regulation of a peptide. One important but commonly overlooked PTM is 
peptide isomerization, where an amino acid residue in the peptide is converted from the L-form 
into the D-form [2-4]. In what follows, the history, function, and formation of DAACPs in 
animals are highlighted. The occurrence and function of DAACPs in bacteria is well established 
and will not be covered in this work. 
Peptide isomerization as a PTM in animals was first demonstrated in dermorphin, a skin peptide 
from the frog Phyllomedusa sauvagei that has high affinity for opioid receptors [5,6]. The 
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structure of dermorphin was found to contain a D-alanine residue that is critical for bioactivity; 
when injected into the rat brain, dermorphin produced an analgesic effect that was up to 1000 
times higher than that of morphine (Fig. 2-1), while a synthetic analog with L-alanine was 
biologically inactive [7,8]. Subsequent studies have shown the presence of peptide isomerization 
in diverse animal systems. Peptides ranging from crustacean hormones [9-11] and molluskan 
neuropeptides [12-16] to the toxins of snails [17-22], frogs [23-28], spiders [29,30], and the 
platypus [31,32] have all been found to contain a D-amino acid in their structure. Interestingly, 
isomerization is not limited to a specific amino acid, as 10 out of the 19 common chiral amino 
acids have been found in the D-form in a peptide. Instead, it is the position of the residue in the 
peptide chain that appears to be important for this PTM [33].  
Peptide isomerization is an important PTM to study because it can greatly influence a peptide’s 
receptor binding properties and metabolism. To begin with, the heterochiral backbone of a D-
amino acid-containing peptide (DAACP) may allow the formation of uncommon structural 
elements in the peptide. For example, the D-amino acid-containing neuropeptide achatin-I, from 
the African giant snail Achatina fulica, was shown to adopt a type II’ beta turn structure that is 
not found in homochiral natural peptides (Fig. 2-2) [34,35]. A structural change upon L to D 
isomerization can substantially alter the bioactivity of a peptide, as most known DAACPs are 
bioactive while their all-L-form counterparts are not. However, there are also cases in which 
bioactivity was reported for both forms of the peptide. In a study of the crayfish hyperglycemic 
hormone (Prc-CHH), the L-isoform CHH-I displayed stronger hyperglycemic activity while the 
D-isoform CHH-II showed greater inhibition of molting activity [10]. This implies that some 
DAACPs may have evolved to broaden the diversity and functional roles of products from a 
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single gene, and the conversion between the peptide isoforms may be regulated based on 
physiological need.  
In terms of peptide metabolism, DAACPs may be degraded more slowly because their altered 
structures make them poor substrates for peptidases (Fig. 2-3) [36,37]. This resistance to 
peptidases lengthens the biological lifetime of a DAACP and allows it to operate on a different 
time scale than its all L-form counterpart, which could be an important factor in DAACP 
signaling events. 
 
2.2 L/D-peptide isomerization in mammals 
Although platypus C-type natriuretic peptide (OvCNb) and defensin-like peptide (DLP-2) are the 
only mammalian DAACPs described so far, there are several lines of evidence that suggest their 
existence in other mammalian systems. First, since amphibian skin peptides frequently have 
counterparts in mammalian gut and nervous systems, a series of studies used antibodies against 
dermorphin to probe for dermorphin analogues in mammalian tissues. Dermorphin-like 
immunoreactivity was observed for tissue extracts from the rat brain and gut, guinea pig stomach, 
and pig brain. Moreover, the isolated immunoreactive material exhibited similar 
chromatographic behavior and aminopeptidase resistance as dermorphin standards [38-41]. 
Second, the discovery of DAACPs also led to the characterization of a new class of enzymes that 
catalyze in-chain peptide epimerization, and similar protein sequences have been found in 
mammalian databases [42-46]. More specifically, a spider peptide isomerase shares sequence 
homology with serine proteases including the human kallikrein and bovine thrombine, and a frog 
peptide isomerase showed sequence similarity to the human IgG-Fc binding protein [42,43]. 
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Third, platypus-like isomerase activity has been detected in the mouse heart, and it would make 
sense that there is an endogenous substrate that is converted into a DAACP [47]. 
Early discoveries of DAACPs mostly resulted from discrepancies in bioactivity-based peptide 
studies. In these experiments, researchers used specific bioassays to isolate a subgroup of 
peptides that demonstrate a particular activity, and then tried to sequence and characterize these 
peptides individually. Sometimes when an active peptide was identified and synthesized for 
further functional studies, a different potency and chromatographic elution was observed for the 
synthetic version compared to the native peptide, and this disparity was eventually found to be 
caused by the presence of a D-amino acid in the native peptide. Considering the need for a robust 
and definitive bioassay, it is not surprising that many of the known DAACPs were found in 
animal toxins and venoms. This does not mean that DAACPs are only prevalent in toxins, just 
that previous studies were biased toward systems that have easily defined and testable bioactivity. 
Another approach for DAACP discovery is to target peptides that are homologous to known 
DAACPs and assess their chirality directly, but this is also limited in scope and unrelated 
DAACP sequences would remain unrecognized.   
In spite of the likelihood that functional DAACPs are broadly expressed in mammals and other 
animals, current research into peptide isomerization is limited by a lack of appropriate analytical 
methods to identify this PTM in a non-targeted manner. Modern peptidomics mainly rely on 
mass spectrometry for the systematic analysis of all peptides in a specific tissue. The problem is 
that L-to-D isomerization does not change the peptide mass, unlike most other PTMs, so it cannot 
be detected with conventional mass spectrometry approaches. While large numbers of peptides 
have been sequenced and identified by tandem mass spectrometry, only a small fraction of them 
are tested for bioactivity. Since functional studies are usually performed using synthetic peptides, 
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a DAACP would likely be passed over as non-functional because its all-L-amino acid synthetic 
peptide is inactive. Therefore, it is reasonable to assume that many DAACPs have been 
overlooked in previous characterizations of the animal peptidome.  
Finally, while the main focus of this study is on physiologically functional signaling peptides 
that are enzymatically modified, there are also cases of spontaneous formation of D-amino acid 
residues that have been observed in aging tissues, most notably in the brain and in the lens of the 
eyes. Isomerization of amino acids in the protein or peptide may cause a change in structure that 
leads to abnormal aggregation [48]. For instance, neurotoxic peptide fragments of β-amyloid 
have been found to contain a D-serine residue in the brains of Alzheimer’s disease patients, and 
α-crystallin proteins with D-aspartic acids are found in the cataract lens [48-50]. Therefore, the 
ability to robustly detect these potential biomarkers would have diagnostic value in several age-
related protein misfolding diseases. 
 
2.3 L/D-peptide isomerases catalyze the formation of DAACPs 
2.3.1 Characterization of the spider isomerase 
The first eukaryotic enzyme that catalyzes the conversion of an L-amino acid residue to a D-
amino acid residue in a peptide chain was purified from the venom of the funnel web spider 
Agelenopsis aperta [30,42]. This isomerase acts on the 48-amino acid peptide ω-agatoxin-TK 




 [42,46]. This D-Ser residue is 
essential for the peptide to function as a selective and potent inhibitor of P-type calcium channels 
in cultured cerebellar Purkinje neurons [30,51]. The complete primary structure of this L/D-
peptide isomerase was determined including the amino acid sequence of a light and heavy chain, 
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the location of four disulfide pairings, and the structure of an N-linked oligosaccharide chain 
[42,52]. The mass of this enzyme is 29 kDa. A sequence homology search showed that the heavy 
chain is similar to serine proteases including the human kallikrein (35% identity) and bovine 
thrombin (26% identity). Isomerase activity was found to convert the Ser
46
 residue 
interchangeably, and both the L→D and D→L reactions were observed (Fig 2-4).  
The substrate specificity of the spider isomerase was explored using a series of short peptides, 
and it was found that the final four amino acid residues of ω-agatoxin-TK was the minimum 
recognition site required for isomerase activity. In addition to the naturally occurring serine 
residue in the substrate, three other amino acid residues were tested for isomerization by the 
enzyme. Both alanine and cysteine residues were converted into the D-form by the isomerase 
while threonine was not. Based on these results, the consensus sequence for the isomerase was 
determined to be Leu-Xaa-Phe-Ala [46].     
The catalytic mechanism of the isomerase was studied by heavy-isotope effects in enzyme 
kinetic experiments [46] and by inhibitory effects of a planar transition state analog that 
incorporates a dehydroalanine in place of the residue to be isomerized [53]. Based on these 
studies, a two-base mechanism was proposed in which proton abstraction from one side of the α-
carbon by the first base is accompanied by proton delivery to the opposite face by a second base 
in the enzyme active site (Fig. 5-5). Isomerase activity was inhibited by phenylmethylsulfonyl 
fluoride (PMSF), which is a serine protease inhibitor, and the isomerase was shown to be 





2.3.2 Characterization of the frog isomerase 
A second L/D-peptide isomerase was isolated from skin secretions of Bombina variegata and 





 (aIle stands for alloisoleucine) [43]. Bombinins H is a family of 
antibiotic and hemolytic peptides that contain L-Ile (in the H1 and H2 peptides) or D-aIle (in the 
H3-H5 peptides) in position 2 of the 21-residue peptide [27]. The mass of this isomerase is 
approximated 52 kDa, and peptide fragments were sequenced by Edman degradation and used to 
clone the N-terminal half of this protein. Since the C-terminal sequence could not be cloned 
successfully, the fragment sequences of the purified Bombina variegata isomerase were used to 
clone a different sequence (coding for a 45 kDa protein) from the related species Bombina 
orientalis, this was then used to identify five homologous isomerase domains in Bombina 
variegata. In a sequence homology search for proteins that are related to the frog isomerase, the 
only major hit was the N-terminal H-doman of the human IgG-Fc binding protein. The frog 
isomerase was also found to catalyze both directions of the isomerization reaction [43].  
Substrate specificity studies of the frog isomerase suggested that a hydrophobic amino acid at 
position 1 and a small amino acid at position 3 of the peptide substrate are essential, while low 
selectivity was found for position 2, as all 13 different amino acid residues that were tested were 
converted by the isomerase. Isomerization occurred at the second residue from the N-terminus 
for all substrates. Several mammalian peptide matching the consensus of the frog isomerase were 
also tested, including the platypus defensin peptide DLP-2[1-6] and the human antimicrobial 
peptide LL-37[1-6], insulin B-chain[1-6], and neuropeptide FF (full length); all yielded 
detectable amounts of the D-form product when incubated with the frog isomerase [54]. 
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The frog isomerase activity was sensitive to diethyl pyrocarbonate (a histidine-specific alkylating 
reagent [55]), suggesting that histidine residues are part of the active site. This is supported by 
the finding that isomerase activity decreased sharply below pH 5.5, when histidine residues 
might be positively charged. When the isomerase assay was performed in tritiated water, 
radioactivity was incorporated into the second residue, implying that the reaction proceeded via a 
protonation/deprotonation mechanism [43]. Planar transition state analogs containing 
dehydroalanine and dehydrophenylalanine residues at the second position were found to be 
potent inhibitors of isomerase activity [56]. Taken together, these studies indicate that the frog 
isomerase also utilizes a two-base protonation/deprotonation mechanism. PLP dependency was 
evaluated by treatment with a PLP inhibitor and by addition of PLP, neither affected isomerase 
activity [43]. 
2.3.3 Characterization of the platypus isomerase 
A third L/D-peptide isomerase was found in the venom gland of the platypus Ornithorhynchus 
anatinus. Interconversion of the Ornithorhyncus venom C-type natriuretic peptides (39 residues; 
OvCNPa contains L-Leu
2
; OvCNPb contains D-Leu
2
) as well as the defensin-like peptides (42 
residues; DLP-4 contains L-Met
2
; DLP-2 contains D-Met
2
) were observed upon incubation with 
the isomerase. The mass of this enzyme was estimated to be around 57 kDa based on SDS-
PAGE, and its sequence is still unknown [44,45].  
Substrate specificities studies were performed using short hexapeptides derived from DLPs. It 
was shown that only the first three residues were required for isomerase activity and the 
isomerase appears to recognize the N-terminal sequence Ile-Xaa-Phe. In addition to methionine 
(found in the native DLP), norleucine and phenylalanine were also converted by the isomerase, 
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out of ten amino acid residues that were tested in position 2. It was proposed that the platypus 
isomerase is specific for substrates that have a long hydrophobic side chain in the second residue 
and a benzene ring in the third residue [57].  
The platypus isomerase was found to be inhibited by diethyl pyrocarbonate but not by 
iodoacteamide or hydroxylamine, suggesting the presence of histidine residue(s) near the active 
site. A candidate gene for the isomerase (mentioned in [57] but not identified) also contains two 
histidine residues in its central region. On the basis of these findings, the platypus isomerase is 
expected to have the same two-base reaction mechanism as the other known isomerases [57]. A 






2.4 Figures and Table 
 
 
Figure 2-1. Dermorphin is a potent opioid receptor agonist. The antinociceptive effect of 
dermorphin and morphine were tested by intracerebralventricular injection. The ED50 for 
dermorphin was in the pmol/rat range for both the hot plate test (●) and the tail-flick test (▲); 
while the ED50 for morphine was ~1000 times higher in the nmol/rat range for the hot plate test 





Figure 2-2. Conformational difference of achatin-I and achatin-II. X-ray crystallography 
data of the D-Phe
2
-containing achatin-I (a) showed a unique turn structure stabilized by two 
intramolecular hydrogen bonds, but this was not observed in L-Phe
2
-containing achatin-II (b) 
because an L-Phe in this position causes steric hindrance between the benzyl group and the 








Figure 2-3. Stability of DAACPs compared to all-L-residue peptides in tissue homogenate. 
Four Aplysia peptides were incubated in Aplysia tissue homogenate and the time course of 
peptide degradation was monitored. DAACPs (GdFFD and GdYFD) showed a higher resistance 
to degradation than all-L-residue peptides (GFFD and GYFD), suggesting that DAACPs may 








Figure 2-4. Activity of the spider isomerase. (A) Conversion of L-TK to D-TK when L-TK was 
incubated with the isomerase. (B) The reverse reaction where D-TK was converted to L-TK by 









Figure 2-5. Proposed two-base mechanism for isomerase reaction. In this mechanism, a 
proton is abstracted from one face of the α-carbon by the first base while another proton is 
delivered to the opposite face by the conjugate acid of the second base in the enzyme active site. 
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3.1 Introduction 
Neuropeptides are a class of cell–cell signaling molecules processed from protein prohormones. 
They are produced in the nervous system and exert effects on virtually all organs, being 
implicated in processes like reproduction [1], food intake [2], and circadian rhythms [3]. The 
proteins used to generate neuropeptides are ribosomally translated using only L-amino acids. 
During this process, they undergo enzymatic post-translational modifications (PTMs), which 
include cleavages by prohormone convertases and additional modifications such as amidation 
[4]. These PTMs are required to create the bioactive form of the peptide. One understudied PTM 
of neuropeptides is peptide isomerization, where roughly 40 DAACPs have been found as toxins, 
neurohormones, and neuropeptides [5,6]. In neuropeptides, this involves the enzymatic 
conversion of one residue near the N-terminus from an L-amino acid to a D-amino acid [5,7-13].  
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However, unlike most other PTMs, isomerization is a zero-Dalton shift in molecular weight and 
so it is not easily detectable by mass spectrometry (MS); several strategies have thus emerged to 
enable isomerization detection [6]. One way to overcome this difficulty is via the use of MS/MS-
based techniques and comparing peptides with only L-amino acids to their DAACP epimers 
[7,14-18]. Recently, MALDI-TOF/TOF was used for the discovery of D-Leu in the peptide GH-2 
[19]. This study also established a stereosensitive fragmentation effect of D-amino acids from 
various amino acid classes on different peptide sequences, which can aid in the discovery of 
DAACPs through MALDI-TOF/TOF by observing the fragmentation ratios of specific peptides. 
Another way to facilitate the discovery is to use bioinformatics to find neuropeptides that are 
homologous to known DAACPs in related species [7]. What is needed is a set of measurement 
techniques capable of identifying DAACPs in a nontargeted manner, rather than targeting a 
suspected DAACP based on homology. 
Other methods, such as those using chemical tags or enzymatic approaches, have been developed 
to detect DAACPs that are formed spontaneously, where racemization of a residue is a 
pathological or aging-related process [18,20-22]. Using photolabile tags combined with electron 
capture dissociation MS, D-Ala, D-Ser, and D-Asp were identified in peptides of lens proteins 
[18]. Isomers of L-Asp, including D-Asp, L-iso-Asp, and D-iso-Asp, were distinguished in lens 
protein peptides using differential enzyme digestion with endoprotease Asp-N, protein-L-
isoaspartyl methyltransferase, and paenidase (D-aspartic acid endopeptidase) [21]. Deuterium 
chloride-assisted acid hydrolysis was also used in conjunction with 4-fluoro-7-nitro-2,1,3-
benzoxadiazole (NBD-F) labeling to identify D-amino acid enantiomers of Ala, Asp, Glu, Pro, 
and Ser in peptides of ovalbumin [22].  
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While these methods have increased the rate and sensitivity of identifying spontaneously forming 
DAACPs, the ability to identify endogenous DAACPs in a complex biological system remains 
elusive. Moreover, these approaches have been directed to specific proteins and also have 
involved the use of standards for initial inquiry, an undesirable option if hundreds of peptides are 
potential DAACPs. If the incorrect L-form of the peptide is tested, this potentially creates a gap 
in peptidomic studies, thereby underestimating the number of biologically active peptides in an 
organism. Since MS has been an enabling tool in modern peptidomic studies, there could be 
DAACPs hiding among the peptides already discovered. 
We report a toolset, or discovery funnel, for the nontargeted detection of DAACPs, particularly 
neuropeptides, that takes the following issues into consideration. First, for neuropeptides (unlike 
spontaneously formed DAACPs and some toxins), isomerization occurs at the second position 
from the N-termini, except for the crustacean neurohormones [23,24]. Second, the variety of 
amino acid residues that are isomerized may include any of the chiral amino acids. When 
including toxin peptides, endogenous DAACPs have included D-amino acid enantiomers of 
aromatic amino acids, polar amino acids, and aliphatic amino acids [5,6]. Thus, a method to 
uncover DAACPs should take advantage of isomerization near the termini and be able to 
simultaneously assay the enantiomers of the 19 common chiral amino acids. Third, there are 
literally hundreds to thousands of brain peptides in most animal models. Thus, requiring peptide 
standards for the initial screening steps for DAACP discovery appears impractical and 
economically infeasible. 
Specifically, the first stage of discovery takes advantage of the fact that DAACPs are resistant to 
peptidases such as aminopeptidase M (APM) (Fig. 3-1, stage 1) [25]. Next, candidate DAACPs 
are isolated and subjected to a chiral amino acid analysis, where deuterium chloride-assisted acid 
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hydrolysis and labeling with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, 
FDAA) are used to assay the chirality of amino acid residues in peptides (Fig. 3-1, stage 2) 
[26,27]. On the basis of information from the chiral analysis, a short list of candidate peptides is 
determined. The peptides of interest are synthesized and their retention times compared to the 
native forms with liquid chromatography (LC) coupled to MS (Fig. 3-1, stage 3). Some MS-
based approaches for DAACP discovery [7,14-18] require a peptide standard for initial inquiry 
or targeting specific sequences, a limitation that is reduced in this method through the use of the 
enzyme APM. Synthetic peptides were also used in the current study for characterization of the 
bioactivity of DAACPs in a system-specific manner. 
We validated the approach using Aplysia californica because two D-amino acid-containing 
neuropeptides have already been identified in its nervous system: NdWFamide (Asn-D-Trp-Phe-
NH2) and GdFFD (Gly-D-Phe-Phe-Asp-OH) [7,28]. More importantly, GdFFD originates from 
the Aplysia achatin-like neuropeptide precursor (apALNP), which produces additional peptides 
[7]. However, whether these additional neuropeptides are DAACPs has not been explored 
because of the lack of a systematic method for their study. Interestingly, in most known cases, a 
single neuropeptide precursor appears to contain a single DAACP [7,10,13]. However, there is at 
least one example where a single precursor produced two DAACPs [11,12]. Thus, we both 
validate our discovery funnel and then use it to determine whether there may be additional 
DAACPs in the Aplysia apALNP precursor. The value of using Aplysia as our model is that its 
neuropeptidome has been the subject of intensive study, and it is an excellent physiological 
model organism [29-35].  
The discovery funnel can be readily applied to investigating biological model systems in which 
DAACPs have not been discovered, uncovering potential DAACPs from any precursor with N-
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terminally modified DAACPs. Indeed, this approach has allowed us to identify three DAACPs 
from a single precursor in Aplysia, suggesting that more DAACPs in Aplysia remain to be 
discovered. 
 
3.2 Experimental Procedures 
Animals. A. californica (120–1200 g) were purchased from Marinus Scientific (Long Beach, CA) 
and the Aplysia Research Facility (Miami, FL). Animals were kept in an aquarium containing 
aerated and filtered artificial seawater (Instant Ocean, Aquarium Systems Inc., Mentor, OH) at 
∼14 °C until used. Prior to dissection, animals were anesthetized by injection of isotonic 333 
mM MgCl2 (about 50% of body weight) into the body cavity. 
Reagents and Peptides. All reagents were purchased from Sigma-Aldrich (St. Louis, MO) 
except where otherwise indicated. NdWFamide was synthesized by the Protein Sciences Facility 
of the Roy J. Carver Biotechnology Center, University of Illinois at Urbana–Champaign. Other 
peptides (GFFamide, GdFFamide, GYFD, GdYFD, SYADSKDEESNAALSDFA, and 
SdYADSKDEESNAALSDFA) were synthesized by CPC Scientific (Sunnyvale, CA). Human 
angiotensin I acetate salt hydrate was purchased from Sigma-Aldrich. 
Cell Sampling of GdFFD Neurons. In situ hybridization data were used as guidance for the 
isolation of neurons expressing the GFFD prohormone (apALNP) [7]. The pedal ganglia were 
dissected and incubated in 1% (w/v) protease (type IX, Bacterial; Sigma P8811) (Sigma-Aldrich, 
St. Louis, MO, USA) in artificial sea water (ASW: 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 
22 mM MgCl2, 26 mM MgSO4, 2.5 mM NaHCO3, and 10 mM HEPES, pH 7.7) supplemented 
with antibiotics (penicillin G, gentamycin, and streptomycin) and maintained at 34 °C for 30 min 
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to loosen the connective tissue sheath. Following a 1 h rinse in ASW with antibiotics to remove 
the bulk of the protease, the ganglia were stretched onto a silicone elastomer (Sylgard, Dow 
Corning, Midland, MI, USA) layer in a Petri dish containing 3–4 ml of the ASW/antibiotic 
medium using 0.15 mm diameter tungsten needles (WPI, Sarasota, FL, USA); the connective 
tissue was surgically removed to expose neurons.  
Clusters of GFFD-expressing neurons were identified according to their relative position to 
prominent morphological landmarks in the ganglion and excised with tungsten needles. The 
clusters were quickly transferred via a plastic micropipette filled with Milli-Q water to remove 
excess salts and deposited onto the MALDI target. Excess liquid was aspirated from the target, 
and spot-to-spot cell transfers were performed for sampling of individual neurons as described 
previously [15,36]. Matrix consisting of 0.5 μl of 2,5-dihydroxybenzoic acid (Sigma-Aldrich), 50 
mg/ml in 50% acetone (Thermo Fisher Scientific, Waltham, MA, USA) was added to each spot. 
An equal volume of matrix and 1 mg/ml synthetic peptides dissolved in water were mixed and 
deposited on the target. 
 Peptide Extraction. For initial screening of DAACPs, neuropeptide extracts from pedal ganglia 
were pooled from 24 euthanized animals (including discovery of GdYFD); follow-up studies for 
SdYADSKDEESNAALSDFAED involved 10 animals. Peptide extraction was performed in 
acidified acetone (40:6:1 acetone: H2O:12 N HCl, v/v/v, acetone and HCl from Thermo Fisher 
Scientific, Waltham, MA), followed by centrifugation at 14 000 rpm, at 4 °C for 20 min 
(Centrifuge 5804R, Eppendorf, Westbury, NY). The supernatant was collected, dried (Savant 
Instruments, Farmingdale, NY), and reconstituted in 5% acetonitrile (ACN) in H2O with formic 
acid (FA) (95% H2O, 5% CH3CN, 0.1% FA v/v/v). 
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APM Screening. Potential DAACPs in A. californica were selected from a complex peptide 
mixture by their resistance to digestion by APM [5,6,25]. APM (EC 3.4.11.2, Merck, Darmstadt, 
Germany) reaction conditions were 25 mM Tris-HCl with 0.5 M NaCl, pH 7.5, reacted at 37 °C 
for 24–48 h, depending on the application (48 h ensures a more thorough digestion for peptide 
isolation). APM (at 60.6 U/mL) was added to be 0.6% of the final reaction volume. Included in 
the digestion experiments were a positive control, human angiotensin I, which is digested by 
APM, and a negative control, NdWFamide, which is not digested by APM [25]. Peptide content 
was compared between 0 and 24 h of the enzymatic digestion. 
Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight (MALDI-TOF) and MALDI-
TOF/TOF Analysis. For APM screening, MALDI-TOF and MALDI-TOF/TOF analyses were 
performed using an ultrafleXtreme mass spectrometer (Bruker Daltonics, Billerica, MA). Mass 
spectra were analyzed using flexAnalysis 3.4 (Bruker Daltonics). The mass was calibrated using 
a peptide mixture of bradykinin 1–7 (757.4 [M + H]
+
), angiotensin II (1046.5 [M + H]
+
), 
angiotensin I (1296.7 [M + H]
+
), substance P (1347.7 [M + H]
+
), bombesin (1619.8 [M + H]
+
), 
ACTH clip 1–17 (2093.1 [M + H]
+
), ACTH clip 18–39 (2465.2 [M + H]
+
), and somatostatin 28 
(3147.5 [M + H]
+
). MS analysis of each neuron was performed in positive-ion reflectron mode. 
The laser size was set to “ultra”, ∼85 μm. Each MALDI-TOF spectrum was summed from 5000 
laser shots, 500 Hz. Selected masses matching to apALNP peptides were chosen for follow-up 
MALDI-TOF/TOF analysis via the “LIFT” mode with argon as the collision gas. 
Sequencing of Peptides. Peptide sequences were confirmed using an LC–MS set up comprised 
of an UltiMate 3000 RSLC system (Thermo Scientific Dionex, Sunnyvale, CA) coupled to an 
amaZon speed ETD mass spectrometer (Bruker Daltonics), by comparing MS/MS fragmentation 
(CID mode) to predicted fragment ions from Protein Prospector 
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(UCSF, http://prospector.ucsf.edu) or fragment ion matching using BioTools 3.2 (Bruker 
Daltonics), fragment mass tolerance 0.2 Da, minimal intensity threshold 800. 
LC–Tandem Mass Spectrometry (MS/MS) for Structure Confirmation. Solvents for LC–
MS/MS were purchased from Thermo Fisher Scientific. To confirm that a peptide was a DAACP, 
peptide standards were synthesized and compared to the endogenous peptides. For this purpose, 
a hyphenated LC–MS/MS platform was employed; the LC instrument was an UltiMate 3000 
RSLC (Thermo Scientific Dionex) and the mass spectrometer was an amaZon speed ETD 
(Bruker Daltonics). The column was a reversed-phase Acclaim PepMap100 C18 (3 μm particle 
size, 100 Å pore size, 300 μm internal diameter (ID) × 15 cm (length) Thermo Scientific Dionex) 
with the following: Buffer A: H2O, 0.1% FA. Buffer B: ACN, 0.1% FA. Loading solvent: H2O, 
0.1% FA. Flow rate: 4 μL/min. For the determination of GdYFD, the gradient started with 4% B 
for 5 min, rising to 15% B in 3 min, then 50% B in 35 min, then 90% B in 1 min and held for 4 
min. The gradient was dropped from 90% B to 4% B and held for 15 min at the end of the 60 
min run. For the determination of SdYADSKDEESNAALSDFA, the gradient started with 5% B 
for 5 min, rising to 10% B in 3 min, then 45% B in 32 min, then 90% B in 1 min and held for 4 
min. The gradient was dropped from 90% B to 5% B and held for 15 min at the end of the 60 
min run. 
Chiral Analysis—Acid Hydrolysis and Amino Acid Labeling. Acid hydrolysis was performed 
on each semipurified peptide fraction in the vapor phase at 150 °C for 30 min in a CEM 
Discover microwave (CEM, Mathews, NC) [37]. The reactions were carried out in 6 M DCl in 
D2O with 0.1% phenol (added to prevent destruction of tryptophan and other amino acids) 
[38,29]. Next, to enhance separation, L- and D-amino acids were derivatized with FDAA 
[26,27]. The amino acids from the acid hydrolysates were dried and reconstituted in 25 μL of 0.5 
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M NaHCO3 (Thermo Fisher Scientific). For derivatization, 20 μL of 1 mg/mL FDAA dissolved 
in ACN were added to these amino acids and reacted at 60 °C for 3 h.  
LC–MS/MS Multiple Reaction Monitoring (MRM) Conditions for the Detection of Labeled 
Amino Acids. Solvents and solutes for chiral analysis were purchased from Thermo Fisher 
Scientific. The LC–MS/MS-MRM setup consisted of an EVOQ Elite Triple Quadrupole Mass 
Spectrometer equipped with the Advance UHPLC module (Bruker Daltonics). The column was a 
Kinetex 2.6 μm particle Phenyl-Hexyl column, 100 Å  pore size, 100 mm (length) × 2.1 mm ID 
(Phenomenex, Torrance, CA). A binary solvent system was used (A, 25 mM ammonium formate; 
B, methanol; flow rate, 300 μL/min). The gradient started with 5% B for 2 min, rising to 15% B 
in 5 min, then 60% B in 5 min and held for 3 min, then 100% B in 3 min and held for 3 min. The 
gradient was dropped from 100% B to 5% B toward the end of the 24 min run. The EVOQ 
source parameters were as follows: HESI, spray voltage (±) 3500 V; cone temperature, 250 °C; 
cone gas flow, 20; heated probe temperature, 400 °C; probe gas flow, 45; nebulizer gas flow, 50; 
exhaust gas, Off. EVOQ MRM chromatograms were analyzed using Data Review 8.2 (Bruker 
Daltonics). A standard mixture of the achiral amino acid glycine and the L- and D-forms of the 19 
common chiral amino acids was derivatized and used in the MRM to establish a table of 
retention times. 
Electrophysiology. Intracellular and extracellular recordings of the physiological activity 
from Aplysia central nervous system preparations (either the cerebral and buccal ganglia, or the 
cerebral and pedal ganglia) were performed as described previously [7,35,40,41]. The ganglia 
were desheathed, transferred to a recording chamber containing 1.5 mL of artificial seawater 
(ASW) (460 mM NaCl, 10 mM KCl, 11 mM CaCl2, 55 mM MgCl2, and 10 mM HEPES, pH 7.6), 
continuously perfused at 0.3 mL/min, and maintained at 14–17 °C. Peptides were dissolved in 
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ASW immediately before each physiological test, and the peptide/ASW solution was perfused 
into the recording chamber. As noted in the Results and Discussion section, some experiments 
were also performed in high divalent (HiDi) saline (368 mM NaCl, 8 mM KCl, 13.8 mM CaCl2, 
115 mM MgCl2, and 10 mM HEPES, pH 7.6), which increases the spiking threshold of neurons 
and therefore curtails polysynaptic influences. Intracellular recordings were obtained using 5–10 
MΩ sharp microelectrodes filled with 0.6 M K2SO4 plus 60 mM KCl. 
To test the peptide effects on the feeding circuit, we included cerebral and buccal ganglia. The 
buccal ganglion innervates the feeding organ (radula). Feeding motor programs were monitored 
by cyclic bursts in the I2 nerve of the buccal ganglion [42,43]. To test the peptide effects on the 
locomotor circuit, we included cerebral and pedal ganglia. The pedal ganglion innervates the foot. 
Locomotor programs were monitored by cyclic bursts in the parapedal commissural nerve of the 
pedal ganglion [44-46]. Electrophysiological recordings were digitized on line using AxoScope 
software (version 9, Molecular Devices, LLC, Sunnyvale, CA) and plotted with CorelDRAW 
(version 11, Corel Corporation, Ottawa, ON, Canada). Bar graphs were plotted using SigmaPlot 
(version 10, Systat, San Jose, CA). Data are expressed as mean ± SE. All statistical tests (e.g., 
repeated measures one-way analysis of variance) were performed using Prism (version 5, 
GraphPad Software, La Jolla, CA). When the data showed significant effects in analysis of 
variance, further individual comparisons were performed with Bonferroni’s correction. 
Behavioral Studies. Peptide effects on locomotor behavior were examined with the method and 
software described recently [40]. Each video recording session used to calculate the locomotor 
path lasted for 25 min. One notable difference with the previous work was that we used a round 
behavior box (diameter, ∼43 cm and height, ∼18 cm) instead of the square behavioral box used 
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previously. We have not observed obvious differences in locomotor behavior between the two 
boxes. 
 
3.3 Results and Discussion 
3.3.1 Discovery Funnel 
The three stages of the discovery funnel involve screening, chiral analysis, and confirmation (Fig. 
3-1). The goal of the first step is to identify suspected DAACPs for follow-up studies, where it is 
acceptable for the first step to have false positives, but it cannot require peptide standards (as it is 
not practical to create standards for all possible DAACPs). Thus, we used enzymatic screening of 
peptides with APM (Fig. 3-1, stage 1). DAACPs are expected to resist degradation by peptidases, 
and indeed APM has been previously shown to degrade peptides containing only L-amino acids 
at a higher rate than DAACPs [25]. We observed a distinct difference in the rates at which the 
all-L-peptides and their corresponding DAACPs were degraded, as demonstrated with GFFD and 
GdFFD. GFFD was rapidly degraded within 5 h, whereas GdFFD was virtually intact after 24 h 
(Fig. 3-1, stage 1), verifying that APM is effective for the screening of potential DAACPs. 
Identifying potential DAACPs by resistance to APM digestion generates false positives because 
in addition to isomerization, specific N-terminal residues and select PTMs increase the resistance 
to APM digestion. For example, peptides with proline at the N-terminus can resist APM 
digestion [25]. In addition, although every D-amino acid-containing neuropeptide discovered so 
far has had isomerization occur at the second residue from the N-terminus, this does not preclude 
the possibility of isomerization occurring at a different residue near the N-terminus 
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[5,6]. Ultimately, the limitations of the first step make the subsequent steps in our method 
necessary. 
The second step is designed to confirm the presence of D-amino acids in suspected peptides and 
so reduces the number of false positives. First, acid hydrolysis is performed in the vapor phase, 
which hydrolyzes the peptide into its component amino acids [37]. While there are several 
possible chromatographic methods, including chiral LC, we derivatized L- and D-amino acids 
with Marfey’s reagent to ensure good separation of all chiral amino acids in one analysis (Fig. 3-
2 and Table 1) [26,27], and detected them with a triple quadrupole mass spectrometer. 
Many peptides are present at low levels in biological samples, making MRM useful for detecting 
the peptide’s constituent D-amino acids after acid hydrolysis because of MRM’s excellent 
signal-to-noise ratio. However, during acid hydrolysis a low rate of amino acid racemization 
occurs. This produces D-amino acids [47], which may lead to the incorrect conclusion of D-
amino acids being present in the original sample. As a solution to this problem, the reactions 
were carried out in 6 M DCl in D2O with 0.1% phenol (added to prevent destruction of 
tryptophan and other amino acids) [38,39]. Under these conditions, digestion-induced 
racemization extracts a deuteron from the solution, causing a shift in mass of 1 Dalton compared 
to an amino acid initially in the D-form. Here, we use MRM to monitor parent ions based on 
their molecular weight within an m/z ± 0.35 window. As a result, a shift of m/z +1 causes acid-
hydrolysis-induced racemization to be undetected in the same channel as the endogenously 
present D-amino acids. In addition, MRM measures the labeled L- and D-amino acid enantiomers 
in different channels in a single analysis step (Fig. 3-1, Stage 2) [48-55]. 
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Interestingly, following DCl-based acid hydrolysis and analysis, labeled tyrosine (Tyr) was seen 
to have a different molecular weight than expected: two more Daltons than the label plus Tyr 
(Fig. 3-3) [38,56]. This observation did not affect the retention time of the labeled L- or D-Tyr in 
the MRM that did not undergo hydrolysis (Fig. 3-3). Tyr can be substituted with chloride during 
acid hydrolysis; rapid vapor phase hydrolysis is meant to help prevent this phenomenon. A shift 
of +1 Dalton may be expected due to random racemization during deuterium-assisted acid 
hydrolysis. However, no racemized residue was detected in the +2 Dalton channel, so it is 
unlikely that the deuteron is on the alpha carbon of the amino acid (which would result in 
racemization). In addition, these amino acids were in solutions that were not deuterated 
following deuterium hydrolysis, so the deuteron is not the result of readily exchangeable 
hydrogens. Rather, the deuteron may result from a substitution reaction in the ortho position on 
both sides, as has been noted with chloride substitutions on Tyr while using acid chlorides. No 
shift was observed in Tyr’s molecular weight following HCl-based hydrolysis (Fig. 3-3).  
For Marfey’s Reagent-based labeling, the L-form was observed to always elute before the D-
form, presumably due to the fixed structure of the tag where the L-amino acid’s side chain will 
be in a trans formation with the –CH3 of L-alanine amide (already on the tag) compared to the 
plane of the benzene ring on the derivatization reagent, whereas the D-amino acid’s side chain 
will be in a cis formation with the –CH3 of L-alanine amide compared to the plane of the benzene 
ring on the derivatization reagent [27,57]. 
This mass shift raises the possibility of other unknown changes during DCl hydrolysis that can 
be observed with MS, which may account for losses of intensity of certain species. DCl 
hydrolysis may not be able to analyze all sequences, as there are amino acids that are destroyed 
(or modified) by acid hydrolysis [58]. Short, high temperature vapor-phase hydrolysis mitigates 
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this, but with low enough levels of neuropeptide, this may not always be sufficient. Also, certain 
sequences do not hydrolyze readily, such as chains of some aliphatic amino acids. 
The final step of the discovery funnel validates the DAACP and involves synthesizing the 
putative peptide in both the all L-form and the D-form. One way to verify structure is to compare 
LC retention times between endogenous and synthetic peptides. In combination with high quality 
MS/MS data [15], a matching retention time from the LC separation for the native peptide and a 
synthetic DAACP is sufficient to confirm the identity of a DAACP (Fig. 3-1, stage 3) [5,6].  
3.3.2 Screening: Peptides from apALNP Resist Digestion to Aminopeptidase M 
apALNP is predicted to produce several peptides and in situ hybridization has indicated that 
apALNP is localized in a cluster of neurons in the pedal ganglia [7]. This led us to consider that 
further DAACP discovery could be facilitated by targeting the pedal ganglia, as the isomerizing 
enzyme is inferred to be expressed by some neurons of this ganglia (the enzyme is currently 
unknown). Extracts from pedal ganglia were subjected to 48 h of APM digestion. After digestion, 
several peptides were seen to resist degradation, including GYFD (Fig. 3-4) and 
SYADSKDEESNAALSDFA (Fig. 3-5). 
Both of these peptides are derived from apALNP. Considering that GdFFD is also present on this 
prohormone, these were promising hits that demonstrated the potential ability of this approach to 
discover novel DAACPs. GFFD was also detected after APM digestion, but was not explored 
further as it is a previously characterized DAACP (data not shown) [7,15]. GYFD and GFFD are 
also homologous and differ only in the second residue. The isomerized residues Tyr and 
phenylalanine (Phe) are both aromatic amino acids. Thus, it would not be surprising that GYFD 
could also exist as GdYFD. Importantly, the peptide was not targeted for its homology, but was 
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chosen here for further studies based on APM screening. While this peptide was not identified in 
MALDI-TOF profiling of the neurons expressing apALNP previously [7], here we detected 
GYFD using MALDI-TOF/TOF from isolated neurons (Fig. 3-6). 
GFFD and GYFD are similar, but there are several longer peptides in apALNP [7]. The other 
observed peptide, SYADSKDEESNAALSDFAED, bears some sequence homology in its N-
terminus to GYFD. Interestingly, a form of this peptide truncated by two C-terminal amino acids 
(SYADSKDEESNAALSDFA) was also seen to resist digestion by APM after 48 h (Fig. 3-5) 
and was identified in previous work [7]. In addition, GFFamide was detected, which has not 
previously been reported as an observed peptide from apALNP. However, this peptide was 
digested by APM (Fig. 3-7), suggesting it is not a DAACP. 
3.3.3 Chiral Analysis: Detection of D-Amino Acids in Peptides Resistant to Digestion 
Endogenous GYFD and SYADSKDEESNAALSDFA were purified to relative homogeneity (Fig. 
3-4 and 3-8), seen to contain a D-Tyr following chiral analysis (Fig. 3-9), and confirmed with 
synthetic GdYFD and SdYADSKDEESNAALSDFA (Fig. 3-4 and 3-10). Thus, we have added 
two new DAACPs to the products from apALNP. In Fig. 3-9, the L-amino acids suggest the 
presence of additional peptides in the fraction containing L-amino acids. These may be low levels 
of the epimeric peptide, which can be somewhat difficult to separate through fraction collection. 
While the epimeric peptides were not detected with LC–MS, the TQ-MS channels are especially 
sensitive to several amino acids over others, based on fragmentation energies (see Fig. 3-2; 
equimolar D- and L-tyrosine favors detection of L-tyrosine, with sometimes dramatic effects, as 
seen in detection of L- and D-threonine). 
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The discovery of GdYFD and SdYADSKDEESNAALSDFA as DAACPs has several interesting 
implications for DAACP formation. This is the first instance of an endogenous DAACP 
containing D-Tyr. In contrast, the peptide GFFamide is not isomerized; as both GFFamide and 
GFFD have Phe in the second position, and yet GdFFamide has not been detected, perhaps the 
ability of the enzyme to isomerize the peptide involves the flanking sequences, as has been noted 
in the frog enzyme [59]. However, GYFD, GFFD, and NWFamide are sequences that are 
recognized by the isomerase, while GFFamide is not. Perhaps GdFFamide does not extract under 
the protocols used, or perhaps it was simply below the limit of detection; therefore, the presence 
of GdFFamide cannot be precluded. 
Our results are defining the endogenous substrates used by a yet unknown isomerizing enzyme 
in Aplysia. It appears to be flexible in regards to sequence and also length. After all, GdFFD is 
only 4 amino acids versus the 20 amino acids of SdYADSKDEESNAALSDFAED. This is 
consistent with studies of the frog enzyme: substrate specificity studies showed the frog 
isomerase was able to act upon sequences of only the N-terminus of the peptide [59].  
3.3.4 GdYFD is Bioactive in the Feeding and Locomotor Circuits of A. californica, whereas 
SdYADSKDEESNAALSDFA is Not 
Previous work has shown that GdFFD is bioactive in both Aplysia feeding [7] and locomotor [41] 
circuits, whereas the all L-amino acid epimer, GFFD is not. We therefore tested whether GdYFD 
and SdYADSKDEESNAALSDFA may also be bioactive in the feeding and locomotor circuits. 
Only GdYFD was found to be bioactive in the feeding (Fig. 3-11) and locomotor networks.  
The physiological data showed that of the two new DAACPs identified from apALNP, only 
GdYFD is bioactive, whereas the other is not. In addition, for GdYFD, similar to our previous 
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study with GdFFD [7], only the DAACP, that is, GdYFD, is active, whereas GYFD is not. 
Finally, our data also suggest that the overall effects of GdYFD and GdFFD in both the feeding 
and locomotor circuits are similar, but the effects of GdYFD may be weaker than GdFFD, 
particularly the effects on CBI-2 programs (Fig. 3-11E) and on fictive locomotor programs. 
Given that each apALNP produces three copies of GdFFD, whereas it only produces one copy of 
GdYFD, the main bioactivity of the peptides from apALNP likely originates from GdFFD. 
Nonetheless, our discovery funnel does provide an effective means to identify functionally 
important DAACPs from multiple peptides originating from a single precursor. 
 
3.4 Conclusion 
We developed and validated a series of protocols we term a DAACP discovery funnel, and used 
it to identify two novel D-amino acid-containing neuropeptides in the nervous system of A. 
californica: GdYFD and SdYADSKDEESNAALSDFA. This method is nontargeted and does 
not require the use of bioactivity to identify novel DAACPs. APM digestion takes advantage of a 
common property of neuropeptide DAACPs: that the modification is found near the N-terminus 
[25]. Although the individual methods have been used in various contexts, this is the first time 
that these methods have been combined into a cohesive workflow and optimized for the purpose 
of endogenous peptide discovery. 
We improved every aspect of these methods, most notably, using triple quadrupole MS for the 
sensitive detection of low levels of D-amino acids, as is necessary for low levels of neuropeptides. 
Because we separate the L- and D-forms into different fractions, the ratio of the L-D forms is less 
important, but the absolute amount of the DAACP must be high enough to characterize with MS. 
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We do note a limitation of this approach: it assumes that the modification occurs near the N-
terminus; if the modification occurs near the C-terminus, our method could miss it. 
Carboxypeptidases may be studied in the future to see if they can achieve the kind of selectivity 
that is seen with APM. Perhaps APM may yet be shown to have the capability to degrade certain 
DAACP sequences more rapidly than anticipated, leading to false negatives. 
Regardless, using this approach, further DAACP discovery efforts are underway in other models, 
including vertebrates. We are actively determining the extent to which post-translational amino 
acid isomerization is found in the nervous systems of animals. In Aplysia, novel peptide 
precursors have recently been identified [61-64]. Our approach can determine if there are 
multiple DAACPs from a single precursor, especially those peptides with little or no bioactivity. 
In mammals, although most bioactive DAACPs are exogenous, several are reported to have 
effects; for example, dermorphin acts upon opioid receptors and has a higher potency than 
morphine [65,66]. Discovery of new DAACPs may provide novel biologics for therapeutic use, 









Figure 3-1. DAACP discovery funnel is capable of identifying DAACPs in three stages, as 
illustrated with GdFFD. In stage 1, MS-based detection of APM digestion is capable of 
identifying potential DAACPs in the screening phase of the discovery funnel. Here, GFFD, used 
as an example, is rapidly degraded after 5 h, whereas its DAACP counterpart, GdFFD, is not 
degraded after 24 h. Both are shown as a ratio to NdWFamide, a peptide that is known to resist 
degradation by APM. In stage 2, chiral analysis utilizes the MRM mode of MS to detect L- and 
D-amino acids in a peptide following acid hydrolysis and labeling.  
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Figure 3-1 (cont.) First, microwave-assisted vapor phase hydrolysis is carried out in DCl to 
break down peptides into their component amino acids. Importantly, DCl-based acid hydrolysis 
reduces detection of racemized residues in peptides. The amino acids are then labeled with 
Marfey’s reagent, separated, and detected using a triple quadrupole mass spectrometer. The 
result of this step is outlined using GdFFD, where a d-Phe is detected. In stage 3, confirmation of 
DAACPs, peptides are synthesized with the suspected chirality at each position and then 
compared to the endogenous peptides. Here, the retention time of the endogenous peptide 







Figure 3-2. Labeled amino acid standard can be separated using LC–MS with a triple 
quadrupole mass spectrometer. Labeling with Marfey’s Reagent leads to separation of all the 
common chiral amino acids.  Their separation allows for identification of D-amino acids in a 







Figure 3-3. Tyrosine (Tyr) had an unexpected molecular weight following DCl-assisted acid 
hydrolysis. DCl-assisted acid hydrolysis of Tyr (red trace) versus HCl-assisted hydrolysis (black 
trace). Tyr reveals that DCl hydrolysis leads to an unracemized (but different molecular weight) 
species. The amino acid used was L-Tyr and the peaks match the retention time of L-Tyr + label 
with no acid hydrolysis (see Figure S1). (A) The expected molecular weight for Tyr + label 
yields a large peak in HCl-assisted hydrolysis, but almost no peak in DCl-assisted hydrolysis. (B) 
In the channel for Tyr + label + 1 Da, there is still almost no molecular species seen in DCl-
assisted hydrolysis, even though a single deuteron would lead to Tyr being detected in this 
channel. There is still a substantial peak for HCl-assisted hydrolysis of Tyr, but this can result 
from naturally occurring carbon and hydrogen isotopes. (C) In the channel for Tyr + label + 2Da, 
there is a large peak in the DCl-assisted hydrolysis, which accounts for the majority of this 
species. This is an unracemized (L-Tyr) species. Meanwhile, little (< 5% of intensity of original 







Figure 3-4. LC–MS/MS characterization of GdYFD, which is confirmed by comparing to the 
retention time of standards. (A) Left, LC–MS (base peak chromatogram) trace of endogenous 
GYFD after 48 h of APM digestion, with a retention time of 15.9 min. Right, the MS/MS 
fragmentation with fragment assignments is shown. (B) Left, an LC–MS trace of the all-l-amino 
acid synthetic GYFD, with a retention time of 14.5 min. Right, the MS/MS fragmentation with 
fragment assignments. (C) Left, an LC–MS trace of the synthetic DAACP GdYFD, with a 
retention time of 15.9 min. Right, MS/MS fragmentation with fragment assignments is shown. 
The matching retention time of the synthetic GdYFD standard with the endogenous GYFD 








Figure 3-5. A. californica endogenous peptide digestions lead to the identification of 
SYADSKDEESNAALSDFA as a potential DAACP. Top: LC–MS trace of an A. californica 
peptide fraction after 48 hours of APM digestion. Black trace: base peak chromatogram of the 
peptide fraction. Red trace: extracted ion chromatogram of m/z 960.4, which with z = +2 
matches SYADSKDEESNAALSDFA. Bottom: MS/MS spectrum of 






Figure 3-6. Direct cell MALDI-TOF MS/MS of neurons expressing the apALNP prohormone 
reveals the presence of GYFD. (A) apALNP from A. californica, with the sequences of interest 
in bold for this study, and others in italic. GFFG was detected as GFFamide in Figure S5. GDAS 
has not been detected. GFFD and YYGS have been detected previously.17 (B) MALDI-MS 
spectrum of neurons that express apALNP, with some peptides assigned based on mass matching. 
(C) MALDI-MS/MS spectrum of GYFD in neurons that express apALNP. GYFD is assigned 
based on the fragment spectra. Parent ion 501.2 m/z. (D) MALDI-MS/MS spectrum of 
SYADSKDEESNAALSDFA in neurons that express apALNP. SYADSKDEESNAALSDFA is 
assigned based on the fragment spectra. Parent ion 1919.8 m/z. (E) MALDI-MS/MS spectrum of 
SYADSKDEESNAALSDFAED in neurons that express apALNP. 






Figure 3-7. GFFamide, another peptide of the apALNP, is not present as a DAACP in the A. 
californica nervous system. (A) The top chromatogram is of an LC–MS (base peak 
chromatogram) trace of endogenous GFFamide. GFFamide was identified in A. californica pedal 
ganglia peptide extracts, but did not resist digestion by APM (data not shown). It had a retention 
time of 23.6 min. The middle LC–MS trace is of GdFFamide synthetic standard, with a retention 
time of 25.9 min. The bottom LC–MS trace is of GFFamide, with a retention time of 23.6 min. 
The endogenous peptide matches that of an all-L-amino acid peptide standard and did not resist 
digestion by APM, establishing that it is not a DAACP. (B) The MS/MS spectrum of GFFamide 





Figure 3-8. MALDI-TOF MS spectrum of a peptide fraction collected from multi-stage LC 
containing endogenous SYADSKDEESNAALSDFA. (A) Results shown demonstrate the 







Figure 3-9. Chiral analysis and LC–electrospray ionization MRM detection of endogenous A. 
californica peptide fractions containing GYFD and SYADSKDEESNAALSDFA are seen to 
have a d-Tyr. (A) Retention times of labeled standard amino acids. (B) Chiral analysis of 
YdAEFLamide peptide standard, to demonstrate the retention time of l-Tyr only. (C) An 
endogenous peptide fraction containing GYFD is seen to contain a d-Tyr. This suggests that the 
endogenous peptide exists as GdYFD. (D) An endogenous peptide fraction containing 
SYADSKDEESNAALSDFA is seen to contain a d-Tyr. This suggests that the endogenous 







Figure 3-10. Through spiking of synthetic standards, endogenous SYADSKDEESNAALSDFA 
is seen to exist as a DAACP, SdYADSKDEESNAALSDFA, in the A. californica nervous 
system. (A) LC–MS (base peak chromatogram) of synthetic peptides of 
SYADSKDEESNAALSDFA (21.6 min) and SdYADSKDEESNAALSDFA (22.4 min) 
demonstrates that both peptides separate. (B) LC–MS (base peak chromatogram) of the 
endogenous SYADSKDEESNAALSDFA spiked with either synthetic 
SYADSKDEESNAALSDFA (black trace) or SdYADSKDEESNAALSDFA (red trace). Black 
trace: Spiking SYADSKDEESNAALSDFA results in two peaks corresponding to 21.6 and 22.4 
min; the endogenous peptide, the second peak, matches the retention time of the DAACP. This is 
confirmed in the red trace where spiking SdYADSKDEESNAALSDFA results in one larger 
peak at 22.4 min, the additive intensity of the endogenous peptide and the standard. This 





Figure 3-11. GdYFD was bioactive whereas GYFD was not in the A. californica feeding circuit 
(with cerebral and buccal ganglia). (A) Perfusion of GdYFD increased activity in the cerebral 
and buccal ganglia (A2) in a concentration-dependent manner (A4, group data). Protraction, 
open bar; retraction, filled bar. Radula closer B8 was mostly active during protraction, so the 
programs were egestive. Note that B65 is strongly active in A2. (B, C) Both GdFFD (B) and 
GdYFD (C) increased B65 excitability in a concentration-dependent manner. Bars in B1 and C1 
indicate current injections in B65. (B2 and C2) Group data. (D) GYFD at 10–5 M had no effects 
on motor programs elicited by stimulation of CBI-2 (9 Hz) (D2). (E) GdYFD at 10–6 M made 
CBI-2-elicited motor programs less ingestive (E2): that is, it reduced protraction duration (E4) 
and reduced B8 activity during retraction (E7). Experiments were performed in ASW, except B 
and C, which were performed in HiDi saline. Bonferroni post hoc test is as follows: *, p < 0.05; 
**, p < 0.01; ***, p < 0.001. 
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Alanine 340 Unit (0.7) 14 278.1 Standard (2.0) 50 - 
Arginine 426.9 Unit (0.7) 10 70.1 Standard (2.0) 50 + 
Asparagine 382.9 Unit (0.7) 33 175.9 Standard (2.0) 50 - 
Aspartatic Acid 384 Unit (0.7) 24 267.9 Standard (2.0) 50 - 
Cysteine 372.1 Unit (0.7) 21 284.9 Standard (2.0) 50 - 
Glutamic Acid 398 Unit (0.7) 24 201.98 Standard (2.0) 50 - 
Glutamine 396.9 Unit (0.7) 20 353 Standard (2.0) 50 - 
Glycine 326.1 Unit (0.7) 32 162 Standard (2.0) 50 - 
Histidine 658.2 Unit (0.7) 30 549.1 Standard (2.0) 50 - 
Isoleucine/Leucine 382 Unit (0.7) 18 319.8 Standard (2.0) 50 - 
Lysine 649.1 Unit (0.7) 36 479.1 Standard (2.0) 50 - 
Methionine 400 Unit (0.7) 17 337.9 Standard (2.0) 50 - 
Phenylalanine 416 Unit (0.7) 20 337.1 Standard (2.0) 50 - 
Proline 365.9 Unit (0.7) 15 321.9 Standard (2.0) 50 - 
Serine 355.9 Unit (0.7) 16 263.9 Standard (2.0) 50 - 
Threonine 370 Unit (0.7) 17 263.9 Standard (2.0) 50 - 
Tryptophan 457.1 Unit (0.7) 10 188 Standard (2.0) 50 + 
Tyrosine 684.1 Unit (0.7) 28 351.95 Standard (2.0) 50 - 
Tyrosine(+2) 686.1 Unit (0.7) 27 353.9 Standard (2.0) 50 - 
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4.1 Introduction 
The discovery of naturally occurring D-amino acid-containing peptides (DAACPs) in animals as 
a result of post-translational L/D-isomerization led to the characterization of a new class of 
enzymes, namely the L/D-peptide isomerases, that are responsible for the biosynthesis of 
DAACPs. Although over 30 DAACPs have been found in diverse animal species, only two 
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peptide isomerases have been purified and sequenced to date, one from spider venom and the 
other from frog skin secretions [1-4]. A third isomerase was isolated and characterized from 
platypus venom, but its sequence is not yet available [5,6]. L/D peptide isomerase activity has 
been detected in a few additional species including the echidna and mouse, but the identity of 
these enzymes are not known [7,8]. 
The spider isomerase acts on the third residue from the C-terminus of a peptide and shares 
sequence homology with serine proteases such as thrombin and kallikrein [2]; the frog isomerase 
acts on the second residue from the N-terminus of a peptide and shares sequence similarity with 
domain H of the human IgG-Fc binding protein, which has no known function [3]. The spider 
and frog isomerases appear to be unrelated, and evidence suggests that the active-site residues 
involved in the reaction are different for each isomerase. The platypus isomerase also isomerizes 
the second residue from the N-terminus, but it is believed to be structurally dissimilar to the frog 
isomerase and does not act on frog-derived peptide substrates [5,6,9,10]. Despite these 
differences, all three of the known peptide isomerases are proposed to catalyze isomerization via 
a two-base mechanism where a proton is removed from one face of the alpha-carbon while 
another proton is added to the opposite face [4,9,11,12], and all isomerase activities were found 
to be independent of PLP and metal ions. 
The presence of a peptide isomerase in Aplysia cailfornica is expected based on the existence of 
the DAACPs NdWFa and GdFFD [13,14]. Furthermore, our discovery of GdYFD and 
SdYADSKDEESNAALSDFA as additional DAACPs [15] suggests that the peptide isomerase 
responsible for the L-to-D modification in Aplysia works only on the second amino acid residue 
from the N-terminus but is promiscuous in terms of peptide length as well as specific residue to 
isomerize, although all isomerized residues found so far have been aromatic amino acids. To 
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advance our understanding of this fascinating enzyme, an assay for characterizing peptide 
isomerase activity was developed.   
Initial efforts focused on dissecting DAACP-expressing regions in the pedal ganglia [14] and 
incubating the homogenate with NWFa as a substrate. Assay conditions were established based 
on studies of other peptide isomerases [2,3,5], and peptide samples post incubation were 
analyzed with a tandem mass spectrometry method where the L- or D-peptide isomer was 
differentiated based on fragment ion ratio [16-18]. This method was relatively fast and simple 
when NWFa and NdWFa were the only analytes, which was helpful for developing initial assay 
parameters. Once isomerase activity was detected in pedal cell homogenates, an alternative 
detection method was developed using liquid chromatography coupled to multiple reaction 
monitoring mass spectrometry (LC-MS/MS-MRM), and the L- or D-peptide isomer was assigned 
based on matching retention times to synthetic standards. The LC-MS analyses are more time 
consuming, but this method is easier to apply to different peptides so that more substrates can be 
tested. 
 
4.2 Experimental Procedures 
Materials. Chemicals and reagents were purchased at the highest grade available from Sigma-
Aldrich (St. Louis, MO) unless otherwise specified. The peptides NWFa, NdWFa, GFFD, and 
GdFFD were synthesized by the Protein Sciences Facility of the Roy J. Carver Biotechnology 
Center at the University of Illinois at Urbana-Champaign. The peptides GYFD and GdYFD were 
synthesized by CPC Scientific (Sunnyvale, CA). LC-MS grade water, acetonitrile, and formic 
acid were purchased from Thermo Fisher Scientific (Waltham, MA). 
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4.2.1 Isomerase assay using tandem mass spectrometry 
Neuron sampling. Aplysia californica (80-200 g) were obtained from the University of 
Miami/NIH National Resource for Aplysia and maintained in aerated and filtered artificial 
seawater at ~14 °C. Animals were anesthetized by an injection of 366 mM MgCl2 equal to half 
of each animal’s body weight before dissection.  The central nervous system (CNS) was 
removed and treated with 1% protease (Protease from Streptomyces griseus) in artificial 
seawater (ASW: 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 16 mM MgSO4, 15 
mM HEPES, 2.5 mM NaHCO3, pH 7.7) at 34°C for 40 min to loosen connective tissues. 
Following protease treatment, the CNS was rinsed in ASW supplemented with antibiotics at 14 
°C for 1 hr to remove the protease. The CNS was then stretched out in a petri dish containing 
ASW, and tungsten needles were used to remove the connective sheath and isolate a region of 
the pedal ganglia containing cells that express GdFFD, a known DAACP. Isolated pedal cells 
were homogenized in ASW, centrifuged at 14,400 x g for 15 min, and the supernatant was used 
immediately for isomerase assays. 
Isomerase assay. Typically, 30 μL of pedal homogenate (roughly containing material isolated 
from two animals) was incubated with 3 μL of 0.1 mg/mL NWFa at room temperature. An 
aliquot of 10 μL was taken from the reaction at each time point (0, 4, 17 hr) and desalted and 
concentrated using C18 ZipTip pipette tips (Millipore, Burlington, MA). Each sample was eluted 
in 1 μL of 50% acetonitrile onto a stainless steel MALDI plate and mixed with 1 μL of 2,5-
dihydroybenzoic acid (DHB) matrix (50 mg/mL in 50% acetonitrile with 0.01% TFA).  
MALDI-TOF tandem mass spectrometry. Tandem mass spectrometry measurements of 
fragment ion ratios for the peptides NWFa and NdWFa were performed in “LIFT” mode with 
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collision-induced dissociation using argon gas on an UltrafleXtreme instrument (Bruker, 
Billerica, MA) as described in Bai et al., 2011 [16]. Briefly, standard NWFa + NdWFa mixtures 
containing 0-100% NdWFa were used to construct a calibration curve showing the correlation 
between a specific fragment ion ratio (b3/b2) and the amount of the D-isomer in a L/D mixture. 
0.7 μL of 1 mg/mL peptide standards were spotted with 0.7 μL of 50 mg/mL DHB in 50% 
acetonitrile with 0.01% TFA, and five replicates were measured for each standard mixture. The 
isomerase assay samples were analyzed under the same conditions, and the b3/b2 fragment ion 
ratio was used to determine the amount of NdWFa in the sample. Data analysis was performed 
using the flexAnalysis and Biotools software (Bruker) and the observed peaks were mass 
matched to predicted fragment ions from Protein Prospector (http://prospector.ucsf.edu). 
4.2.2 Isomerase assay using LC-MS/MS-MRM 
Enzyme preparation. Aplysia californica (100-200 g) were anesthetized by an injection of 366 
mM MgCl2 equal to half of each animal’s body weight before dissection. Neural ganglia were 
removed from each animal, homogenized in PBS with 5 mM ethylenediaminetetracetic acid 
(EDTA), and centrifuged at 15,000 x g for 20 min. The supernatant was filtered through a 0.45 
μm syringe filter and adjusted to a 1 M ammonium sulfate solution by drop wise addition of 
saturated (4 M) ammonium sulfate, left on ice for 20 min, then centrifuged at 12,500 x g for 10 
min. The supernatant was then fractionated on an AKTA fast protein liquid chromatography 
(FPLC) system (GE Healthcare Life Sciences, Marlborough, MA) with hydrophobic interaction 
chromatography on a Phenyl-Superose HR 5/5 column (GE Healthcare Life Sciences) at a flow 
rate of 0.5 mL/min. The buffer was 25 mM Tris-HCl pH 8.3 with 5 mM EDTA, and the gradient 
was 1 M to 0 M ammonium sulfate over 15 column volumes. 40 fractions were collected at 0.5 
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mL/Fr; each fraction was tested for isomerase activity and active fractions were used as the 
enzyme sample in subsequent assays. 
Isomerase assay. For each assay, 50 μL of enzyme sample was buffer-exchanged into 30 μL of 
50 mM phosphate buffer with 5 mM EDTA, pH 6 (this is the standard assay buffer) using a 
Nanosep Centrifugal Device with the Omega 10 kDa MWCO membrane (Pall Corporation, Port 
Washington, NY). The enzyme sample was incubated with 2 μL of 5 μg/mL peptide substrate at 
37 °C for 24 h unless otherwise stated. Samples were desalted and concentrated with solid-phase 
extraction using C18 ZipTip pipette tips according to the product manual. Peptides were eluted 
in 20 μL of 50% acetonitrile in water with 0.1% formic acid. 
LC-MS/MS-MRM analysis. Isomerase assay samples were analyzed with a multiple reaction 
monitoring system where signals for each targeted peptide were monitored in a separate channel 
based on the m/z values of both the parent ion and specific fragment ions. An all-L-peptide and 
its corresponding DAACP would be detected in the same channel since they have the same 
amino acid sequence, but the peptide isomers can be separated by LC based on their different 
shape. Peptide standards were used to establish MRM channels and optimize LC conditions to 
ensure separation of the L- and D-form peptide isomers. The system consisted of an Advance 
ultra-high performance LC coupled to an EVOQ triple-quadrupole mass spectrometer (Bruker), 
the column was a Kinetex 1.7 μm C18 column, 100 Å, 150 x 2.1 mm (Phenomenex, Torrance, 
CA), and the solvents were water with 0.1% formic acid (solvent A) and  acetonitrile with 0.1% 
formic acid (solvent B). The 20 min LC gradient was 5-50% B for 15 min, 50-80% B for 1 min, 
80% B for 1 min, 80-5% B for 1 min, 5% B for 2 min at a flow rate of 300 μL/min. 
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Glycoprotein isolation. ConcanavalinA (conA)-based glycoprotein isolation was performed 
using a ConA Glycoprotein Isolation Kit from Thermo Fisher Scientific. Since EDTA interferes 
with glycoprotein binding to the lectin resin, 100 μL of enzyme sample was first exchanged into 
400 μL of EDTA-free assay buffer using a Nanosep 10 kDa MWCO centrifugal device. For each 
sample, 200 μL of 50% resin slurry was transferred to a spin column, which was centrifuged for 
1 min at 1000 x g after each step to collect flow-through. The resin was rinsed three times with 
200 μL of 1x Binding/Wash Buffer each time. The 400 μL sample was diluted with 100 μL of 5x 
Binding/Wash Buffer and incubated together with the resin for 10 min at room temperature with 
end-over-end mixing. Save the flow-through, and wash the resin four times with 400 μL of 1x 
Binding/Wash Buffer each time. To elute the bound glycoproteins, 200 μL Elution Buffer was 
added to the resin and incubated for 10 min. Collect the eluate and repeat the elution step with 
another 200 μL Elution Buffer. Finally, concentrate and exchange the saved flow-through sample 
and eluted glycoprotein sample back into the standard assay buffer before an isomerase assay. 
Wheat germ agglutinin (WGA)-based glycoprotein isolation was performed in the same way 
using a WGA Glycoprotein Isolation Kit from Thermo Fisher Scientific. 
Glycosidase treatment. Peptide-N-glycosidase F (PNGase F, 500,000 units/mL) was purchased 
from New England Biolabs (Ipswich, MA). For each reaction, 27 μL of the isomerase-containing 
sample (~20 μg total protein) was combined with 3 μL of GlycoBuffer 2 (10x) and 5 μL of 
PNGase F, mixed gently, and then incubated at 37 °C for 24 h. After PNGase F treatment, the 
sample was exchanged into 30 μL of the standard assay buffer using a Nanosep 10 kDa MWCO 
membrane and subjected to the standard isomerase assay. 
Planar substrate analogs. The peptides GΔFFD-OH, GΔAFDSKDY-NH2, and 
GΔFFDSKDEKdAdY-NH2 were synthesized with a dehydrophenylalanine (ΔF) or 
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dehydroalanine (ΔA) residue at the second position; GΔAFDSKDY-NH2 and 
GΔFFDSKDEKdAdY-NH2 contain an ε-biotinylated lysine as a molecular handle; and 
GΔFFDSKDEKdAdY-NH2 was designed with D-amino acids at the C-terminal to increase 
resistance to carboxypeptidases. 
 
4.3 Results and Discussion 
4.3.1 Isomerase assay using tandem mass spectrometry 
Tandem mass spectrometry is capable of distinguishing between L- and D-peptide isomers based 
on differential fragmentation patterns [17,18]. In the case of NWFa and NdWFa, the ratio of the 
b3 ion to the b2 ion was found to be most critical for epimer discrimination [16]. As 
demonstrated in Fig. 4-1A, when NWFa was fragmented via collision-induced dissociation in 
tandem MS, the intensities of the b2 and b3 ions were roughly the same, but when NdWFa was 
fragmented, the intensity of the b3 ion was higher than the b2 ion. With the construction of a 
calibration curve using standard L/D mixtures of different compositions (Fig. 4-1B), the b3/b2 
ratio can be used as a chirality reporter to determine the fraction of the D-form peptide in an L/D 
mixture according to the following equation:  
ln RM = ln ( RL ) + ln ( Rchiral ) * α,  
where RM is the experimentally measured b3/b2 ratio; RL and Rchiral are based on the calibration 
curve, and α is the mole fraction of the D-form.  
Fig. 4-2 shows the result for an isomerase assay using the tandem MS approach. In this 
experiment, regions of the pedal ganglia that contain DAACP-expressing neurons were dissected 
and homogenized in ASW. The L-form peptide NWFa (465.2 m/z) was then added to the 
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homogenate as a substrate. At the start of the reaction, tandem MS of the mass peak at 465.2 m/z 
yielded a fragmentation pattern that matches NWFa, where the intensity of the b2 ion was 
roughly the same as the b3 ion. After 4 h of reaction, the fragmentation pattern was markedly 
different, with the b3/b2 ion ratio closer to that of NdWFa. At 17 h in the reaction, the b3/b2 ion 
ratio corresponded to around 80% NdWFa as calculated using the calibration curve. This 
suggested an isomerizing activity in the pedal cell homogenate that converted NWFa into 
NdWFa over time.    
4.3.2 Isomerase assay using LC-MS/MS-MRM  
Although the tandem MS approach works well for distinguishing NWFa and NdWFa, the 
difference in fragmentation patterns between L- and D-peptide isomers tends to be less 
pronounced for longer peptide sequences, making it harder to assign chirality based on fragment 
ion ratios. Therefore, an LC-MS approach was developed in which the L- and D-peptide isomers 
were eluted from the column at different times because of their different structural shape (Fig. 4-
3). In these analyses the L/D assignment was based on matching the retention time of the sample 
peak to that of the L- or D-peptide standard. 
In Aplysia, NdWFa is localized to the abdominal ganglia and achatin-like neuropeptide 
prohormone-derived peptides (GdFFD, GdYFD, and SdYADSKDEESNAALSDFA) are 
localized to the pedal ganglia [14,16,19,13,15]. Therefore, both the abdominal and pedal ganglia 
are expected to exhibit peptide isomerase activity. It was hypothesized that the L-form peptides 
NWFa, GFFD, and GYFD would be converted into DAACPS when incubated with abdominal or 
pedal ganglia extracts.  
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Fig. 4-4 shows the result of an experiment in which GFFD was incubated in pedal ganglia 
extracts. A peak in the GFFD MRM channel (theoretically only molecules with the correct 
parent and fragment m/z values would be detected in the channel) was observed at a retention 
time matching to the GdFFD standard, indicating that GdFFD was detected post-incubation. A 
control where GFFD was incubated without the enzyme fraction resulted in detection of GFFD 
only, ruling out spontaneous L-to-D conversion. A control of enzyme fraction without adding the 
substrate showed that GdFFD was not endogenously present in the enzyme fraction. Furthermore, 
a tube containing the enzyme fraction was placed in boiling water for 10 min prior to incubation 
with GFFD, and L-to-D conversion was not observed with heat treatment. This supports the idea 
that L-to-D conversion of peptides in ganglia extracts was the result of an enzymatic activity. 
Taken together, these results indicate that GFFD was converted to GdFFD in pedal ganglia 
extracts. Similarly, Fig. 4-5 shows the conversion of NWFa to NdWFa in abdominal ganglia 
extracts and the conversion of GYFD to GdYFD in pedal ganglia extracts.  
To facilitate further studies of the isomerase and with the goal of identifying the sequence of this 
unknown enzyme, assay conditions were evaluated and optimized with GFFD as the standard 
substrate. All major neural ganglia in the CNS (buccal, cerebral, pedal, pleural and abdominal) 
were used for enzyme preparation. In particular, the effects of temperature and incubation time 
were analyzed. As shown in Fig. 8-6, the isomerase activity increased from 4 °C to 37 °C and 
was abolished at 60 °C. Although isomerase activity was observed at 14 °C, which is the 
physiological temperature for our Aplysia animals, the highest activity was found at 37 °C, 
which was chosen as the standard assay temperature. A time course experiment showed that 
reaction equilibrium was reached when roughly 60% of the peptides were in the D-form (Fig. 4-
7). This conversion equilibrium is similar to values that were reported for the spider isomerase 
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assay (~70% D-form) and the frog isomerase assay (~50% D-form) [2,3]. Other aspects of 
enzyme preparation and assay procedures were studied, including the tissue amount and storage 
conditions, protein fractionation techniques, assay buffers, reaction volume, and sample clean-up 
protocols. Fig. 4-8 compares the result of a typical assay before and after method optimization, 
the extent of isomerization that could be detected in an assay was greatly improved after 
optimization.  
4.3.3 Glycoprotein isolation 
The spider isomerase is known to be a glycoprotein with an N-linked oligosaccharide chain 
consisting of a trimannosyl core structure, Man3-GlcNAc2-Fuc, that is covalently attached to 
Asn127 of the heavy chain [2]. Although glycosylation of the frog isomerase has not been 
studied in detail, the active enzyme was purified on a ConA-Sepharose column and eluted with 
methylmannoside in the glycoprotein fraction [3]. In light of this, we decided to explore the 
possibility that the Aplysia isomerase also exists as a glycoprotein. This information not only 
aids in enzyme purification and identification, it is also relevant for any protein expression 
studies in the future.  
Glycoprotein isolation was performed on Aplysia neural ganglia extracts using two types of 
lectin resins. The concanavalin A (conA) lectin has a selective affinity for α-linked mannose and 
terminal glucose residues, and the wheat germ agglutinin (WGA) lectin preferentially binds N-
acetyl glucosamine (GlcNAc) and sialic acid. In both cases, isomerase activity was detected in 
the flow-through but not the elution fraction, indicating that the isomerase did not bind to the 
lectin resin (Fig 4-9). To assess whether a carbohydrate moiety might be required for isomerase 
activity, we incubated an isomerase fraction with peptide-N-glycosidase F (PNGase F), which is 
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an amidase that cleaves between the innermost GlcNAc and asparagine residues of N-linked 
glycoproteins [20]. Isomerase activity was detected even after treatment with PNGase F, which 
argues against the presence of a critical carbohydrate moiety (Fig 4-9). However, further studies 
are needed to confirm the glycosylation state of the Aplysia isomerase.  
4.3.4 Planar substrate analogs 
A two-base mechanism involving protonation/deprotonation at the α-carbon of the amino acid 
residue to be isomerized has been proposed for all three of the known L/D-peptide isomerases in 
animals [9,11,12]. A carbanionic intermediate is formed during this reaction, and compounds 
that mimic the structure of this planar transition state can act as strong inhibitors of the enzyme 
as well as useful probes for understanding the structural and chemical basis of enzyme catalysis. 
Well-known examples include the inhibition of the proline racemase by planar transition state 
analog pyrrole-2-carboxylic acid [21] and inhibition of the glutamate racemase by planar 
enamine and imine compounds [22,23]. Moreover, both the spider and frog L/D-peptide 
isomerases were found to be inhibited by planar transition state peptide analogs that contained 
dehydroalanine or dehydrophenylalanine in place of the amino acid residue that is normally 
isomerized [11,12]. These findings were important evidence used to establish the reaction 
mechanism of the isomerases.  
As a first step toward elucidating the catalytic mechanism of the Aplysia isomerase, three 
peptides were designed and synthesized to mimic the planar transition state molecule in a two-
base mechanism. These peptides are analogs of the standard substrate GFFD and contain 
dehydroalanine or dehydrophenylalanine at the second position instead of phenylalanine. Two of 
the peptides contain a biotin handle that could be utilized for affinity purification if the analog 
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peptide was found to be a potent inhibitor that was tightly bound to the isomerase, as seen in the 
case of the frog isomerase. Isomerase assays were performed in the presence of each of the 
planar substrate analogs, and the results showed that GΔFFD (where ΔF represents 
dehydrophenylalanine) had a slight inhibition effect while the two longer analogs had no effect 
on isomerase activity (Fig.4-11).  
A more detailed study was conducted on GΔFFD, and the results are shown in Fig. 4-12. First, 
since the cis/trans stereochemistry of the dehydrophenylalanine residue was not established 
during synthesis, the GΔFFD peptide was heated to 70 °C and cooled to room temperature in an 
attempt to equilibrate the stereoisomers. An assay was performed at a lower temperature (~20 °C 
room temperature instead of 37 °C) because of this consideration. Multiple concentrations of 
GΔFFD were tested, at inhibitor (GΔFFD) to substrate (GFFD) ratios of 20:1, 5:1, and 1:1. 
Finally, inhibition of the reverse reaction (GdFFD to GFFD) was tested using GdFFD as the 
substrate. Once more, GΔFFD showed only a slight inhibition effect on the conversion of GFFD 
to GdFFD and seemed to have no effect on the reverse reaction. This is in stark contrast to 
studies of the frog and spider isomerases, where the dehydroalanine or dehydrophenylalanine 
substrate analogs were found to be potent inhibitors for isomerase activity. It is possible that the 
Aplysia isomerase employs a different reaction mechanism, and additional mechanistic studies 
are necessary for further insight on this enzyme. 
 
4.4 Conclusion  
An assay for detecting L/D peptide isomerase activity was developed in Aplysia californica. 
Since the peptides NdWFa, GdFFD and GdYFD are known to exist as DAACPs, the all-L-forms 
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of these peptides were used as substrates to evaluate peptide isomerase activity. The 
corresponding DAACPs were detected post incubation, suggesting that isomerase activity is 
indeed active in the tissues. The isomerase assay was optimized to facilitate further studies in 
enzyme purification and characterization. Glycoprotein assessment and enzyme mechanism 




4.5 Figures  
   
 
Figure 4-1. Differential fragmentation of NWFa and NdWFa using tandem MS. A. Mass spectra 
showing the fragmentation patterns of NWFa and NdWFa. The ratio of the b3/b2 ions is different 
for the L- and D-peptide isomers. B. Calibration curve showing the correlation between 
ln(intensity of b3/intensity of b2) and the ratio of the D-isomer in an LD mixture. Five technical 
replicates were made for each LD mixture. 
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Figure 4-2. MS/MS profiles of 465.2 m/z in a sample of NWFa incubated with pedal cell 
homogenates. At the start of incubation, the MS/MS profile matched the L-isomer NWFa. Over 
time, the MS/MS profile shifted closer to the D-isomer NdWFa, indicating that the content of 
NdWFa in the sample increased. After 17 hr of incubation, the peptide content was estimated to 
be around 80% NdWFa based on the calibration curve in Figure 4-1.    










































































Figure 4-4. GFFD was converted to GdFFD in pedal ganglia extracts. 1st panel: GFFD and 
GdFFD standards were separated by retention time in LC-MS. 2nd panel: GdFFD was detected 
post-incubation. 3rd panel: GdFFD was not detected when the enzyme fraction was heated in 
boiling water prior to incubation. 4th panel: a control of GFFD incubated with buffer did not 
show spontaneous isomerization. 5th panel: a control of enzyme fraction incubated for the same 
length of time showed that GdFFD was not present endogenously.   
GFFD+GdFFD standards 
GFFD + enzyme fraction 
Control:  
GFFD + buffer (no enzyme) 
Control:  
Enzyme fraction only (no substrate) 






           
 
Figure 4-5. NWFa was converted into NdWFa in abdominal ganglia extracts and GYFD was 
converted into GdYFD in pedal ganglia extracts. Left: NWFa as substrate. Right: GYFD as 
substrate. 1st panel: L-form and D-form standards were separated by retention time in LC-MS. 
2nd panel: D-product was detected post-incubation. 3rd panel: a control of L-substrate incubated 
with buffer did not show spontaneous isomerization. 4th panel: a control of enzyme fraction 








































Figure 4-6. The effect of incubation temperature on isomerase activity. Left: MRM 
chromatograms showing formation of GdFFD (arrow) at different temperatures. Right: 
temperature profile for isomerase activity. In these assays, GFFD was incubated with an enzyme 































Figure 4-7. Time course of the conversion of GFFD to GdFFD. Left: MRM chromatograms 
showing the formation of GdFFD (arrow). Right: GFFD was incubated in an isomerase fraction 














Figure 4-8. Comparison of isomerase assay before and after optimization. Left: in an early assay, 
isomerase activity was low and only a few percent of the standard substrate GFFD was converted 
into GdFFD in an enzyme fraction. Right: after assay optimization, isomerase activity reached 
70% conversion when GFFD was incubated at 37 °C for 24 h.  
  






           
 
Figure 4-9. Glycoprotein tests. Left: glycoprotein isolation using the concanavalin (conA) lectin 
was performed on ganglia extracts. A control assay was included using the enzyme sample prior 
to gycoprotein isolation. Formation of D-product (arrow) was detected in the flow-through but 
not the eluent of the conA isolation, indicating that the isomerase did not bind to conA. Middle: 
glycoprotein isolation using the wheat germ agglutinin (WGA) lectin. As seen with conA, the 
isomerase did not appear to bind to WGA. Right: isomerase activity was detected after treatment 
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Figure 4-10. Structures of planar substrate analogs designed to mimic the transition state 





Figure 4-11. Effect of synthetic planar substrate analogs on isomerase activity. 1st panel: a 
control of L-substrate incubated with buffer did not show spontaneous isomerization. 2nd panel: 
a control of L-substrate incubated with an isomerase fraction. D-product was detected post-
incubation (arrow). 3rd panel: the planar substrate GΔFFD was incubated with GFFD and 
isomerase fraction. Isomerase activity appears to be suppressed by the addition of GΔFFD. 4th 
and 5th panel: addition of the planar substrates GΔAFDSKDYa or GΔFFDSKDEKdAdYa did 
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Figure 4-12. The effect of GΔFFD on isomerase activity was studied in more detail using 
another isomerase fraction. 1st panel: a control of L-substrate incubated without GΔFFD. D-
product was detected post-incubation (arrow). 2nd panel: GΔFFD was added and incubated at 
room temperature. 3rd - 5th panel: GΔFFD was added at a ratio of 20:1, 5:1, and 1:1 to GFFD 
and incubated with the isomerase fraction at 37 °C. 6th and 7th panel: the reverse reaction using 
GdFFD as the substrate was assayed with and without the addition of GΔFFD. 
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The presence of D-amino acid residues in bioactive gene-encoded peptides results from a post-
translational modification in which an L-amino acid residue is enzymatically converted into the 
D-form [1-3]. This unique class of D-amino acid-containing peptides (DAACPs) often exhibit 
increased potency and protease stability over their unmodified all-L-form isomers [4-17]. 
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Although a growing number of naturally occurring DAACPs have been discovered, the extent 
and physiological function of this modification in animal peptides is not well-studied, largely 
because routine peptide characterizations based on mass spectrometry does not assess the 
chirality of amino acid residues in a peptide [18-20]. Likewise, little is understood about how D-
amino acid residues are incorporated into eukaryotic peptides, and only three L/D-peptide 
isomerases from the spider venom, frog skin secretion, and platypus venom have been 
characterized to date [21-29]. The discovery of these enzymes provided the first clues into the 
biosynthesis of DAACPs in animals, but much remains to be explored about the timing, 
regulation, and mechanism of peptide isomerization.    
The marine mollusk Aplysia caifornica is a valuable model in neurobiology because of its large, 
accessible, and identifiable neurons [30-32]. A large number of neuropeptides have been 
identified in Aplysia neurons using molecular biology and mass spectrometry-based techniques, 
and many of them were found to have sequence similarities to mammalian neuropeptides [33-35]. 
Of particular interest to this study is the identification of several DAACPs in the Aplysia 
neuropeptidome, including the peptide NdWFamide (where “d” indicates that the following 
residue is a D-amino acid residue) and three related peptides derived from the achatin-like 
neuropeptide precursor, GdFFD, GdYFD, and SdYADSKDEESNAALSDFA [36,16,17]. 
NdWFamide is known to be involved in the regulation of cardiac activity in Aplysia kurodai 
[14,37], and GdFFD and GdYFD were found to be bioactive in the feeding and locomotion 
neural circuits in Aplysia californica [16,17,38]. For all three peptides, only the DAACP-isomer 
was bioactive while the all-L-isomer was not (NdWFamide was active at 10
-10
 M while 
NWFamide had no effect at 10
-5
 M; GdFFD and GdYFD were active at 10
-5
 M while GFFD and 
GYFD had no effect at 10
-6
 M). These studies demonstrate the functional importance of L/D-
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isomerization in neuropeptides and provide evidence for the existence of an L/D-peptide 
isomerase in the Aplysia nervous system.   
In the present work, we hypothesized that a neuronal enzyme in Aplysia californica is capable of 
isomerizing the second amino acid residue of certain neuropeptides. We established a liquid 
chromatography-mass spectrometry (LC-MS) based assay and used it to confirm isomerase 
activity in neuronal tissues. Despite the challenge in detecting minute amounts of enzyme 
activity in the highly complex matrix of the nervous system, we were able to perform partial 
characterization of this novel enzyme and advance the understanding of L/D-peptide 
isomerization in animals.  
 
5.2 Experimental procedures 
Materials. Chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise specified. The peptides NWFa, NdWFa, GFFD, and GdFFD were synthesized by the 
Protein Sciences Facility of the Roy J. Carver Biotechnology Center at the University of Illinois 
at Urbana-Champaign; GYFD and GdYFD were synthesized by CPC Scientific (Sunnyvale, CA); 
GAFD, GLFD, GWFD, GSFD, GKFD, GDFD, and GdSFD were synthesized by Genscript 
(Piscataway, NJ); GdAFD, GdLFD, GdWFD, GdKFD, and GdDFD were synthesized by solid-
phase peptide synthesis as described [39]. LC-MS grade water, acetonitrile (ACN), and formic 
acid (FA) were purchased from Thermo Fisher Scientific (Waltham, MA). 
Animals. Aplysia californica (100-200 g) were obtained from the University of Miami/NIH 
National Resource for Aplysia and housed in an aquarium with 14 °C aerated and filtered 
artificial seawater (Instant Ocean, Blacksburg, VA) Animals were used within one week of 
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arrival. Prior to dissection, animals were anesthetized by an injection of 366 mM MgCl2 at 50% 
(v/w) body weight into the body cavity. Neural ganglia and other tissues were dissected from 
each animal and stored at -80 °C until used. 
Enzyme isolation. Neural ganglia were homogenized in ice-cold 20 mM Bis-Tris with 5 mM 
ethylenediaminetetracetic acid (EDTA), pH 7, using a PowerGen 125 homogenizer (Fisher 
Scientific). The homogenate was centrifuged at 15,000 x g for 20 min and the supernatant was 
filtered through a 0.45 μm syringe filter. The filtrate was fractionated on a HiTrap ANX Fast 
Flow (high sub) column (GE Healthcare Life Sciences, Marlborough, MA) using a step-wise 
elution of 0 M, 0.25 M, 0.5 M, and 1 M NaCl. The 0.5 M NaCl elution fraction was buffer-
exchanged and adjusted into 25 mM Tris-HCl with 5 mM EDTA and 1 M ammonium sulfate. 
The sample was then fractionated on a Phenyl-Superose HR 5/5 column (GE Healthcare Life 
Sciences) using the AKTA fast protein liquid chromatography (FPLC) system (GE Healthcare 
Life Sciences). The running buffer was 25 mM Tris-HCl with 5 mM EDTA, pH 8.3, and the 
gradient was 1 M to 0 M ammonium sulfate over 15 column volumes at a flow rate was 0.5 
mL/min. Fractions were collected every 0.5 mL and each fraction was tested for isomerase 
activity. Active fractions were store at -80 °C and used as the enzyme sample in subsequent 
assays. 
Isomerase assay. For each assay, 50 μL of enzyme sample was concentrated and exchanged into 
30 μL of 50 mM phosphate buffer with 5 mM ethylenediaminetetraacetic acid (EDTA), pH 6 
(standard assay buffer) using a Nanosep Centrifugal Device with Omega 10 kDa MWCO 
membrane (Pall Corporation, Port Washington, NY). For assays where protease inhibitors were 
added, a 100x stock of the protease inhibitor was diluted into the standard assay buffer to 1x 
working concentration and used for buffer exchange. For cofactor dependence assays, the assay 
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buffer included (1) no EDTA, (2) 2 mM MgCl2, (3) 4 mM ATP, (4) 20 μM pyridoxal 5’-
phosphate (PLP), or (5) 1 mM aminooxyacetic acid (AOAA). 2 μL of 5 μg/mL peptide substrate 
was added to the enzyme sample and incubated at 37 °C for 24 h unless otherwise stated. 
Samples were desalted and concentrated with solid-phase extraction using reversed-phase C18 
ZipTip pipette tips (Millipore, Burlington, MA) prior to LC-MS analysis. Briefly, the sample 
was adjusted to 0.1% trifuoroacetic acid (TFA), pH < 4; the ZipTip was washed twice with 10 
μL ACN and twice with 10 μL 0.1% TFA in water, then the sample was loaded onto the resin by 
aspirating and dispensing the sample 10 times through the tip. The tip was then washed three 
times with 10 μL of 5% methanol in water with 0.1% TFA to remove salts and unbound 
molecules. The purified peptide sample was eluted in 20 μL of 50% ACN in water with 0.1% FA. 
LC-MS/MS-MRM analysis. Isomerase assay samples were analyzed in the multiple reaction 
monitoring (MRM) mode on an LC-MS/MS system that consisted of an Advance UHPLC 
coupled to an EVOQ Elite Triple Quadrupole Mass Spectrometer (Bruker, Billerica, MA). The 
LC column was an XSelect CSH C18 3.5 μm column, 4.6 x 150 mm (Waters, Milford, MA), and 
the solvents were water with 0.1% FA (solvent A) and ACN with 0.1% FA (solvent B). The 15 
min gradient was 5-15% B in 2 min, 15-30% B in 8 min, 30-70% B in 1 min, 70% B for 1 min, 
70-5% B in 1 min, and 5% B for 2 min, at a flow rate of 1 mL/min. The MS was operated with 
the following parameters: heated electrospray ionization (HESI) source, (±) spray voltage = 4000 
V, cone temperature = 250 °C, cone gas flow = 20, heated probe temperature = 400 °C, probe 
gas flow= 45, and nebulizer gas flow = 50. MRM chromatograms were analyzed using MS 





5.3 Results and Discussion 
5.3.1 L/D peptide isomerase activity 
Isomerase activity was evaluated in terms of the stereochemical conversion of the phenylalanine 
residue at position 2 as determined by LC-MS/MS-MRM analysis of the reaction products using 
GFFD and GdFFD as substrates. As shown in Fig. 5-1, both the L- and D-configuration of Phe
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in the substrate peptide were inverted when incubated with an isomerase fraction. Under our 
assay conditions, 52% of GFFD was converted to GdFFD after 24 h of incubation, but only 17% 
of GdFFD was converted to GFFD during the same period. This confirmed that the isomerization 
process is reversible and suggests that the L-to-D reaction is faster than the D-to-L reaction, as is 
the case for all endogenous substrates for other L/D-peptide isomerases in animals 
[21,24,26,25,27].  
The distribution of isomerase activity in the Aplysia central nervous system as well as two 
peripheral tissues was assessed. Fig 5-2 shows that isomerase activity was detected in all major 
neural ganglion (buccal, cerebral, pedal, pleural, and abdominal ganglion) but not in the gill or 
buccal mass, which is the feeding apparatus in this animal. Previous characterizations of 
DAACPs in Aplysia californica have shown that NdWFamide is present in the abdominal 
ganglion [36], and the achatin-like neuropeptides GdFFD, GdYFD, and 
SdYADSKDEESNAALSDFA are mostly expressed in the pedal ganglion [16,17,39]. Therefore, 
our results confirmed the predicted presence of an isomerase in the abdominal and pedal 
ganglion, but isomerase activity in the buccal, pleural and cerebral ganglion also hint at the 
existence of undiscovered DAACPs throughout the central nervous system and support the 
hypothesis that L/D-peptide isomerization is a widespread PTM in neuropeptides. 
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In this assay for isomerase activity, the pH optimum was found near pH 5.75, and there was little 
activity beyond pH 7. This is interesting because the pH of organelles is critical for protein 
processing and trafficking and becomes progressively more acidic as the cargo moves through 
the secretory pathway [40,41]. Although measurements differ based on the method and cell type 
used, it is estimated that the pH changes from ~7.2 in the endoplasmic reticulum to 6.7 - 6.0 in 
the Golgi complex to 6.0 - 5.2 in the secretory vesicles. In our case, an acidic pH optimum is 
consistent with a neuropeptide processing enzyme found in the secretory pathway, as is expected 
for an L/D-peptide isomerase, instead of a cytosolic enzyme that is active under neutral pH. 
5.3.2 Substrate specificity 
In order to gain more insight into the substrate requirements of the isomerase, we assayed a 
series of seven analogs of the standard substrate GFFD that contain a single residue substitution 
at the second position (Fig. 5-4 and Table 5-1). We found that all three proteinogenic aromatic 
amino acid residues at the second position (phenylalanine, tyrosine, and tryptophan) can be 
converted by the isomerase. A very small amount of conversion for observed for an L-leucine 
residue at position 2, and no isomerization was detected for the other GFFD analogs (with 
alanine, serine, aspartate and lysine at position 2).  
This specificity toward aromatic residues at position 2 is distinct from the frog isomerase, which 
has a low selectivity for residues at position 2, and all 13 amino acid residues tested were 
isomerized [29]. On the other hand, the platypus isomerase was found to convert methionine, 
norleucine, and phenylalanine at position 2, out of the 11 amino acid residues that were tested 
[27]. Further studies are needed to elucidate other substrate requirements (for example the effect 
of flanking residues in position 1 and 3) for the Aplysia isomerase. If a consensus sequence is 
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determined, it can also be used to screen a database of endogenous peptides to identify putative 
substrates for the isomerase, which are likely to exist as DAACPs.  
5.3.3 Inhibition of isomerase activity 
Enzyme inhibitors are useful tools for probing the reaction mechanism and structure of enzymes, 
since the same types of compounds can often be used as inhibitors for the same types of 
enzymatic reactions [42,43]. In previous experiments we discovered that addition of a protease 
inhibitor cocktail to the assay mixture had an inhibitory effect on isomerase activity. Here, we 
tested individual components of the protease inhibitor cocktail (Fig. 5-5) and evaluated their 
effect on isomerase activity. Of the five inhibitors that were tested, 4-(2-
aminoethyl)benzenesulfonyl fluoride (AEBSF) was the only one that resulted in partial inhibition 
of isomerase activity (Fig. 5-6). In a time course experiment of the isomerization of GFFD with 
and without the addition of 1 mM AEBSF, 71% of the reaction products were in the D-form in 
the control sample after three days of incubation, but only 18% D-form was observed for the 
sample that contained AEBSF (Fig. 5-7).  
Since AEBSF is known to irreversibly inhibit serine proteases by forming a sulfonyl enzyme 
derivative with the hydroxyl group of an active site serine residue, our results suggest that a 
serine or threonine residue may be involved in the catalytic mechanism of the Aplysia isomerase 
[44,45]. Interestingly, the spider isomerase was inhibited by 1 mM phenylmethylsulfonyl 
fluoride (PMSF), which is a serine protease inhibitor similar to AEBSF [22], and its protein 
sequence was also found to share similarities to serine proteases in a homology search [21]. In 
contrast, the frog isomerase was not inhibited by PMSF, but it was found to be sensitive to 
diethyl pyrocarbonate and hypothesized to have a histidine residue in the active site [24]. The 
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platypus isomerase was found to be inhibited by amastatin, which is an aminopeptidase inhibitor 
[25]. Although it is tempting to think that the Aplysia isomerase is most similar to the spider 
isomerase, it should be noted that the spider isomerase acts on the third residue from the C-
terminus of its peptide substrate [22,13] instead of on the second residue from the N-terminus as 
in the case of the Aplysia, frog, and platypus isomerases. It is likely that there are different 
classes of enzymes that are capable of catalyzing L/D-peptide isomerization.  
5.3.4 Cofactors 
We also examined the cofactor requirement of the isomerase enzyme in terms of its dependence 
on metal ions, ATP, and PLP (Fig. 5-8). Depletion of 5 mM EDTA from the standard assay 
buffer had no significant effect on isomerase activity, which argues against the presence of 
divalent metal ions as cofactors. Addition of 2 mM MgCl2 or 4 mM ATP were tested because of 
their modulating effects on many amino acid racemases [46-48], but neither was found to affect 
the Aplysia L/D-peptide isomerase activity. Finally, the inability of 20 μM PLP or 1 mM AOAA 
(a PLP-inactivating reagent [49,50]) to influence the isomerase reaction suggests that the enzyme 
operates independently of PLP as a cofactor.     
 
5.4 Conclusion 
We developed an LC-MS based enzyme assay and used it to investigate an L/D-peptide 
isomerase activity in the central nervous system of Aplysia californica. The broad distribution of 
isomerase activity across the nervous system suggests that peptide isomerization is a prevalent 
post-translational modification and implies the existence of more undiscovered D-amino acid-
containing neuropeptides. This is the first study of a neuronal enzyme that catalyzes L/D-peptide 
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isomerization in animals, and efforts are underway to purify and identify the sequence of this 
novel enzyme.  
107 
 
5.5 Figures and Table 
 
Figure 5-1. Interconversion of GFFD and GdFFD. GFFD was incubated with an isomerase 
fraction in 50 mM phosphate buffer with 5 mM EDTA, pH 6, at 37 °C. Samples were analyzed 
at 0 h (brown trace) and 24 h (green trace). In another reaction, GdFFD was incubated with the 
isomerase fraction under the same conditions and analyzed at 0 h (red trace) and 24 h (blue trace). 
Arrows point to the product of the reactions.  
L 
D 
Enzyme fraction + GFFD, 0 h 
Enzyme fraction + GFFD, 24 h 
Enzyme fraction + GdFFD, 24 h 




Figure 5-2. Distribution of isomerase activity in different tissues. Isomerase activity was 
detected in all major ganglion in the central nervous system but not in the buccal mass (muscle) 





































Figure 5-3. pH dependency of isomerase activity. Assays were performed with GFFD as the 
substrate at pH 4, 5, 5.5, 5.75, 6, 6.5, 7, and 8, at 37 °C for 24 h. The data from three replicates 




























             
 
             
 
Figure 5-4. MRM chromatograms showing the isomerization reactions for GFFD analogs with 
different amino acid residues at position 2 (green traces). Retention times of the L- and D-form 
standards for each peptide are shown in brown traces, and arrows indicate the formation of the D-
product. Each substrate was assayed 3 times and representative chromatograms are shown.  
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Figure 5-5. Compounds that were tested for their ability to affect isomerase activity. AEBSF: 
irreversible inhibitor of serine proteases. Bestatin: competitive, reversible inhibitor of 
aminopeptidases. Aprotinin: reversible, competitive inhibitor of serine proteases 
(www.sigmaaldrich.com). Leupeptin: reversible inhibitor of cysteine, serine and threonine peptidases. 
E64: irreversible inhibitor of cysteine proteases. 
E-64  
MW = 357.41 g/mol 
Leupeptin 




Figure 5-6. Five compounds were tested for inhibitory effects on isomerase activity. GFFD was 
incubated in enzyme fractions containing 1 mM AEBSF (green), 1 μM aprotinin (red), 50 μM 
bestatin (blue), 15 μM E-64 (magenta), or 20 μM leupeptin (yellow) at 37 °C for 24 h. AEBSF 
was found to cause partial inhibition of isomerase activity. 
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Figure 5-7. Time course of isomerization reaction and the inhibitory effect of AEBSF. GFFD 
was incubated in isomerase fractions at 37 °C for 0, 2, 4, 24, and 72 h in the absence (circles) and 






























Figure 5-8. Cofactor dependency of the isomerase. GFFD was incubated with isomerase 
fractions in buffers that contain no EDTA, 5 mM EDTA, 2 mM MgCl2, 4 mM ATP, 20 μM PLP, 
and 1 mM AOAA (PLP-inactivating reagent) at 37°C for 24 h. Data from three replicates were 











































GFFD aromatic + + + 
GWFD aromatic + + + 
GYFD aromatic + 
GAFD small - 
GLFD nonpolar (+) 
GSFD polar - 
GKFD (+) charged - 
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D-amino acid-containing peptides (DAACPs) in animals are a class of bioactive peptides formed 
through enzymatic conversion of a specific L-amino acid residue into a D-amino acid residue in 
the peptide chain [1-3]. This post-translational modification causes a change in the three-
dimensional structure of the peptide molecule that can affect a peptide’s interaction with its 
receptor as well as peptidases, thereby altering its function and stability. Enzymes that catalyze 
the isomerization of amino acid residues in the synthesis of DAACPs in animals are named L/D-
peptide isomerases, and only three such enzymes found in the spider, frog, and platypus have 
been reported to date [4-6]. In previous work, we established an assay for studying the activity of 
a fourth L/D-peptide isomerase found in the central nervous system of Aplysia californica. This 
is the first neuronal enzyme that catalyzes neuropeptide isomerization in animals, whereas the 
three known isomerases were found in venoms and skin secretions. We investigated the 
characteristics of the Aplysia isomerase including its tissue distribution, pH dependency, 
substrate specificity, inhibitors, and cofactor requirements, but the sequence of this enzyme 
remains unknown.  
In the case of the spider isomerase, the enzyme was purified to homogeneity from the crude 
venom of Agelenopsis aperta by a single round of size exclusion chromatography [4]. Enough 
protein was isolated for structural determination through a combination of amino acid analysis 
and automated Edman degradation of peptide fragments generated by endopeptidase digestion. 
The isomerase was found to consist of a light chain and a heavy chain connected by a disulfide 
bond, as well as three additional intramolecular disulfide bridges. Additionally, carbohydrate 
analysis was used to determine the presence of an N-linked oligosaccharide in the heavy chain. 
Based on these results, the complete primary structure of spider isomerase was established.  
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In the case of the frog isomerase, an apparently homogenous protein (as judged by SDS-PAGE) 
was purified from 500 milkings of skin secretions of Bombina variegata through a glycoprotein 
isolation procedure followed by two rounds of size exclusion chromatography and three rounds 
of ion exchange chromatography [5]. The partial N-terminal sequence of the protein was 
determined by automated Edman degradation and used for cloning experiments with mRNA 
isolated from the skin. A cDNA fragment representing the first half of the isomerase was found, 
but the C-terminal half of this protein remains unknown. 
 Isomerase activity in Aplysia californica is found in the central nervous system, and endogenous 
DAACPs are neuropeptides that act as cell-to-cell signaling molecules [7-9]. Due to the 
complexity of a tissue matrix compared to venoms or skin secretions, and because a 
neuropeptide processing enzyme is expected to be present at a relatively low level compared to 
other proteins in the cell, we anticipated that it would be highly difficult to purify the Aplysia 
isomerase to homogeneity. In the present study, we used liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS) to identify proteins in partially purified isomerase 
samples based on statistical matching of MS data to a protein database [10-12]. We also analyzed 
the differential gene expression between a DAACP-expressing cell type and a control cell type 
that presumably lacks neuropeptides. On the basis of these data, we identified 11 protein 
sequences as candidates for the Aplysia isomerase, and we are in the process of expressing these 







6.2 Experimental procedures 
Materials. Chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise noted. The peptides GFFD and GdFFD were synthesized by the Protein Sciences 
Facility of the Roy J. Carver Biotechnology Center at the University of Illinois at Urbana-
Champaign. LC-MS grade water, acetonitrile (ACN), and formic acid (FA) were purchased from 
Thermo Fisher Scientific (Waltham, MA). 
6.2.1 Activity-based enzyme purification 
Animals. Aplysia californica (100-200 g) were ordered from the Aplysia Resource Facility in 
Miami, FL, kept in an aerated aquarium of artificial seawater (Instant Ocean, Blacksburg, VA) at 
14 °C, and used within one week of arrival. Typically 20 animals were used for each single-stage 
purification experiment; 20-40 animals were used for each two-stage purification experiment; 
and 40-100 animals were used for the 3-stage purifications. For dissection, animals were 
anesthetized with an injection of isotonic MgCl2 at 50% of body weight (v/w) into the body 
cavity. The buccal, cerebral, pedal, pleural, and abdominal ganglia were removed and kept 
frozen at -80 °C until used. Typically, the ganglia were homogenized in PBS with 5 mM 
ethylenediaminetetracetic acid (EDTA) at 1 mL per 100 mg tissue unless specified otherwise. 
The homogenate was centrifuged at 23,700 x g for 20 min at 4 °C, and the supernatant was 
filtered through a 0.45 μm syringe filter before protein fractionation. 
Ion exchange chromatography. Anion-exchange chromatography was performed on a Mono Q 
HR 5/5 column (GE Healthcare Life Sciences, Marlborough, MA) on an AKTA fast protein 
liquid chromatography (FPLC) system (GE Healthcare Life Sciences) with 20 mM Tris-HCl 
with 5 mM EDTA, pH 8.3, as the buffer. The salt gradient was 0 to 1 M NaCl over 10 min at a 
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flow rate of 1 mL/min. Cation-exchange chromatography was performed on a Mono S HR 5/5 
column (GE Healthcare Life Sciences) with 50 mM sodium phosphate with 5 mM EDTA, pH 6, 
as the buffer. The salt gradient was 0 to 1 M NaCl over 10 min at a flow rate of 1 mL/min, and 
fractions were collected every 1 mL throughout the run. For S-Q ion exchange experiments, the 
protein sample was passed through a Mono S column, and then the flow-through was 
fractionated over a Mono Q column on the FPLC. The running buffer was 20 mM HEPES, 5 
mM EDTA, pH 7.4, and the salt gradient was 0 to 1 M NaCl over 10 min at 1 mL/min flow rate.  
Additional ion-exchange media and buffer conditions were screened using the HiTrap IEX 
Selection Kit (GE Healthcare Life Sciences). Five 1 mL HiTrap columns including the cation 
exchangers SP Sepharose Fast Flow and CM Sepharose Fast Flow, and the anion exchangers Q 
Sepharose Fast Flow, DEAE Sepharose Fast Flow, and ANX Sepharose 4 Fast Flow (high sub) 
were tested. Three pH values were tested for every column- for cation exchangers the start 
buffers were (1) 50 mM acetic acid, pH 5, (2) 50 mM MES, pH 6, and (3) 50 mM sodium 
phosphate, pH 7; for anion exchangers the start buffers were (1) 20 mM Bis-Tris, pH 7, (2) 20 
mM Tris, pH 8, and (3) 50 mM diethanolamine, pH 9. All buffers contained 5 mM EDTA. The 
separation was performed with a syringe at a flow rate of ~1 mL/min, and the elution buffer was 
the start buffer with 1 M NaCl. 
For multi-stage experiments that used the ANX anion exchanger, the columns were 1 mL or 5 
mL HiTrap ANX FF (high sub) operated with a syringe using 20 mM Bis-Tris with 5 mM EDTA, 
pH 7, as the start buffer. The flow rate was ~1 mL/min for the 1 mL column and ~5 mL/min for 
the 5 mL column. In a purification run, the column was first washed with 5 column volumes (CV) 
of start buffer and 5 CV of the start buffer with 1 M NaCl, and then equilibrated with 5 CV of the 
start buffer. The protein sample was applied to the column and the flow-through was re-loaded 
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once. Next, the column was washed with 5 CV of the start buffer. Stepwise elution was 
performed with 3 CV each of start buffer with 0.25 M NaCl, start buffer with 0.5 M NaCl, and 
start buffer with 1 M NaCl. After elution, the column was washed with 5 CV start buffer with 1 
M NaCl, then 10 CV start buffer, then rinsed with water and stored in 20% ethanol.  
Hydrophobic interaction chromatography. The protein sample (~5 mg total protein) was 
adjusted to a 1 M ammonium sulfate solution by drop-wise addition of saturated (4 M) 
ammonium sulfate, left on ice for 20 min, then centrifuged at 12,500 x g for 10 min. The 
supernatant was loaded onto a Phenyl-Superose HR 5/5 column (GE Healthcare Life Sciences) 
on the FPLC system and fractionated at a flow rate of 0.5 mL/min. The buffer was 25 mM Tris-
HCl pH 8.3 with 5 mM EDTA, and the gradient was 1 M to 0 M ammonium sulfate over 15 
column volumes. 40 fractions were collected at 0.5 mL/Fr, and each fraction was tested for 
isomerase activity. 
Size exclusion chromatography. The protein sample (< 5 mg total protein) was concentrated and 
exchanged into 200 μL PBS with 5 mM EDTA, loaded onto a Superose-12 10/300 GL column 
(GE Healthcare Life Sciences) on the FPLC system, and fractionated with PBS as the buffer for 
1.5 column volumes (~36 mL). The flow rate was 0.2 mL/min, and 60 fractions were collected at 
0.5 mL/Fr.  
Isomerase assay. For each assay, 50 μL of protein fraction was buffer-exchanged into 30 μL of 
50 mM phosphate buffer with 5 mM EDTA, pH 6, using a Nanosep Centrifugal Device with the 
Omega 10 kDa MWCO membrane (Pall Corporation, Port Washington, NY). 2 μL of 5 μg/mL 
GFFD peptide substrate was added to each sample and incubated together at 37 °C for 24 h. 
Samples were desalted and concentrated with solid-phase extraction using C18 ZipTip pipette 
127 
 
tips (Millipore, Burlington, MA) according to manufacturer’s instructions, and peptides were 
eluted in 20 μL of 50% ACN in water with 0.1% FA. Isomerase assay samples were analyzed on 
an LC-MS/MS system with an Advance ultra-high performance LC coupled to an EVOQ triple-
quadrupole mass spectrometer (Bruker, Billerica, MA). The LC column was an XSelect CSH 
C18 3.5 μm column, 4.6 x 150 mm (Waters, Milford, MA), and the solvents were water with 
0.1% FA (solvent A) and ACN with 0.1% FA (solvent B). The 15 min gradient was 5-15% B in 
2 min, 15-30% B in 8 min, 30-70% B in 1 min, 70% B for 1 min, 70-5% B in 1 min, and 5% B 
for 2 min, at a flow rate of 1 mL/min. The MS was operated in the multiple reaction monitoring 
(MRM) mode with mass channels specific for GFFD and GdFFD. 
Protein identification using LC-MS/MS. Protein identification was performed by the Protein 
Sciences Facility of the Roy J. Carver Biotechnology Center. Sample clean-up was done using 
the Perfect-FOCUS kit (G-Biosciences, St. Louis, MO) according to manufacturer’s instructions. 
After clean-up, the protein sample was digested with MSG-Trypsin (G-Biosciences) at a w/w 
ratio of 1:10 using a Discover Microwave Reactor (CEM Corporation, Matthews, NC) at 55 °C 
at maximum power of 60 W for 30 min. Digested peptides were lyophilized in a Virtis-55 
lyophilizer (SP Scientific, Warminster, PA) to dryness, then dissolved in 5% ACN with 0.1% FA 
prior to LC-MS analysis. The LC-MS system consisted of a Dionex UltiMate RSLC3000 
(Thermo) operating in nano mode at 300 μL/min with a gradient from water with 0.1% FA to 
ACN with 0.1% FA in 120 min. The trap column was an Acclaim PepMap 100 (Thermo), 100 
μm x 2 cm, and the analytical column was an Acclaim PepMap RSLC (Thermo), 75 μm x 15 cm. 
2 μg of the digested peptides were loaded per injection. MS was performed on an LTQ Fusion 
Orbitrap Mass Spectrometer (Thermo) using data dependent top speed mode for MS/MS analysis 
on the top most intense ions detected in the precursor scan mode. Previously detected ions were 
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automatically excluded for 60 s to allow deeper coverage of the less abundant ions. For data 
analysis, the Xcalibut raw files were converted by Mascot Distiller (Matrix Science, Boston, MA) 
into peak lists that were submitted to an in-house Mascot Server and searched against the NCBI-
Prot protein database for Aplysia californica. The peptide mass tolerance was 10 ppm, the 
fragment mass tolerance was 0.3 Da, and the significance threshold was set to p < 0.05.  
6.2.2 RNA sequencing 
Cell isolation. The whole CNS was isolated and incubated in 1% protease IX in artificial 
seawater (ASW, 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 16 mM MgSO4, 15 
mM HEPES, 2.5 mM NaHCO3, pH 7.7) supplemented with antibiotics at 34 °C for 40 min to 
digest the outer connective tissue. Following a 1 h wash in ASW with antibiotics, the sheath was 
removed from the cerebral and pedal ganglia, and the MCC cells and GFFD-expressing cells and 
were identified based on their relative position, morphology, and size. The cells were excised 
with tungsten needles and quickly transferred either to a tube containing RNA Lysis Buffer (for 
RNA sequencing) or to a MALDI target (for confirming GFFD expression).      
MALDI-TOF MS analysis. A matrix solution of 30 mg/mL 2,5-dihydroxybenzoic acid in 50% 
ACN was applied over the cells in each target spot and air-dried. Cells samples were analyzed by 
an UltrafleXtreme mass spectrometer (Bruker) in positive-ion reflectron mode, and each 
spectrum was a sum of 2000 laser shots. Mass spectra were analyzed using flexAnalysis version 
3.4 (Bruker).  
RNA extraction. RNA from the GFFD and MCC cells was prepared using the Quick-RNA 
MicroPrep Kit (Zymo Research, Irvine, CA). All steps were performed at room temperature, and 
all centrifugation steps were performed at 12,500 x g. Isolated cell (MCC) or cell cluster (GFFD) 
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were placed directly into 100 μL RNA Lysis Buffer (three animals per sample) after dissection. 
100 μL ethanol was added to the sample, mixed well, and transferred to a Zymo-Spin IC Column 
in a collection tube and centrifuged for 30 s. The flow-through was discarded. The column was 
washed with 400 μL RNA Wash Buffer, centrifuged for 30 s, and the flow-through was 
discarded. To prepare the DNase I Reaction Mix, 5 μL DNase I (reconstituted as indicated on the 
vial) was added to 35 μL DNA Digestion Buffer and mixed by gentle inversion. The 40 μL 
DNase I Reacion Mix was added directly to the column matrix, incubated for 15 min, and then 
centrifuged for 30 s. 400 μL RNA Prep Buffer was added to the column, centrifuged for 30 s, 
and the flow-through was discarded. 700 μL RNA Wash Buffer was added to the column, 
centrifuged for 30 s, and the flow-through was discarded. 400 μL RNA Wash Buffer was added 
to the column and centrifuged for 2 min to ensure complete removal of the wash buffer, and then 
the column was transferred into an RNase-free tube. 15 μL DNase/RNase-Free Water was added 
directly to the column matrix and centrifuged for 30 s. The eluted RNA was stored at -80 °C 
until used. 
RNA sequencing. Library preparation and sequencing were performed by the High-Throughput 
Sequencing and Genotyping Facility of the Roy J. Carver Biotechnology Center. RNA libraries 
were prepared using the TruSeq Stranded mRNAseq Sample Prep Kit (Illumina, San Diego, CA), 
quantitated by qPCR, and sequenced on one lane with reads 150 nt in length for 151 cycles from 
each end of the fragments on a HiSeq 4000 system (Illumina) using a HiSeq 4000 sequencing kit 
version 1. Fastq files were generated and demultiplexed with the bcl2fastq v2.17.1.14 
Conversion Software (Illumina). Gene expression analysis was performed by the High 
Performance Biological Computing Facility of the Roy J. Carver Biotechnology Center. Raw 
reads were trimmed to remove adapter content and low quality bases using Trimmomatic version 
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0.36. Reads were aligned to NCBI’s Aplysia californica reference genome AplCal3.0 using the 
STAR software, version 2.5.3a, and gene counts were generated using featureCounts, version 
1.5.2. The raw read counts were input into R [13] (v 3.4.1) for pre-processing and analysis 
together using Bioconductor [14] packages as listed below. We used TMM method [15] in the 
edgeR package [16] (v 3.18.1) normalize the counts to log2-transformed counts per million 
(logCPM), using the cpm() function with prior.count = 3.  TMM-values and logCPM normalized 
values were re-calculated with prior.count = 3. A surrogate variable accounting for the difference 
in one of the MCC replicates was added to edgeR’s quasi-likelihood negative binomial 
generalized log-linear model [17], which was fit on the original read counts + TMM values to 
find differential expression between the neuron types. Multiple hypothesis test correction was 
done using the False Discovery Rate method [18]. The logCPM values were further adjusted for 
gene length using edgeR’s rpkm function for down-stream applications. 
 
6.3 Results and Discussion 
6.3.1 Activity-guided enzyme purification 
In order to isolate the Aplysia isomerase for sequence identification and characterization studies, 
a series of protein purification techniques were explored. Separations were performed under non-
denaturing conditions to maintain enzyme activity, so reversed-phase chromatography methods 
using organic solvents were excluded. Affinity chromatography was not an option because 
affinity tags are not available for the isomerase. However, multiple protein separation methods 
based on ion exchange, hydrophobic interaction, and size exclusion chromatography were tested, 
both individually and in combination. Tissue extracts were prepared from Aplysia neural ganglia 
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and fractionated using each method, and protein fractions were assayed for isomerase activity. 
Table 6-1 is a summary of the results of these purification experiments. For protein fractionation 
based on ion exchange chromatography, a selection of five different media was tested as the ion-
exchanger, and three pH values were tested for every media (Table 6-2).  
The final purification scheme was a three stage method in which neural ganglia extracts were 
first passed through an ANX anion exchange column (Fig. 6-1). In the activity profile of this first 
step (Fig. 6-2), isomerase activity was found in the 0.5 M NaCl elution fraction while most of the 
substrate degradation was observed in the 0.25 M NaCl fraction. This shows that the first stage 
purification was effective at removing interfering peptidase activity from the isomerase sample. 
Further purification of the isomerase sample was achieved on a Phenyl-Superose hydrophobic 
interaction column in the second stage (Fig. 6-3) and then on a Superose-12 size exclusion 
column in the third stage (Fig. 6-4). 
6.3.2 Protein identification using LC-MS/MS 
After a three-stage purification, selected fractions (ANX-HIC-SEC Fr16/22/24/26/28/29/35, 
isomerase activities shown in Fig. 6-5) spanning across the isomerase activity profile were 
subjected to protein analysis using an LC-MS/MS approach. Protein samples were digested with 
trypsin and analyzed using LC-MS/MS, and the data was searched against the NCBI protein 
database for Aplysia californica using the Mascot software, which compares MS data to 
predicted masses from the protein database and assign proteins that match statistically with the 
experimental data.  
As summarized in Fig. 6-6, a total of 658 unique protein hits were identified from all the 
fractions, and 387 hits were found in the active fractions (Fr24 or Fr26 or Fr28). Among these 
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387 hits, 66 protein sequences were predicted to contain a signal peptide using the SignalP 4.1 
Server [19,20]. Since the Aplysia isomerase acts on neuropeptides, it is expected to be localized 
to the secretory pathway where neuropeptides are synthesized and processed, and proteins that 
contain a signal peptide sequence for sorting into the secretory pathway are more likely to be the 
isomerase. 11 out of the 66 proteins were excluded as isomerase candidates because they are 
well-studied neuropeptide prohormones (7B2, allatotropin-like, egg-laying hormone, pleurin, 
PRQFVa, sensorin-A, and whitnin), neuropeptide processing enzymes (carboxypeptidase E and 
prohormone convertase-2) and known receptors (ROR and soluble acetylcholine receptor). The 
remaining 55 proteins are considered candidates for the isomerase, and 31 of these candidates 
were also detected in previous purification experiments. At this point, considering that 100 
animals were used for this three-stage purification experiment and that even more animals would 
be needed for further purification, we tried to obtain complementary information from another 
prospective that may help narrow down the isomerase candidate list. 
6.3.3 RNA sequencing of GFFD and MCC cells 
In the study that identified GdFFD as a DAACP in Aplysia, expression of the GFFD precursor 
gene was localized with in situ hybridization [8]. In the present study, we used RNA sequencing 
to compare gene expression between GFFD cells, which express DACCPs and presumably also 
express the isomerase, and metacerebral cells (MCC), which appear to lack neuropeptides and 
presumably also lack neuropeptide processing enzymes including the isomerase [21,22]. The 
hypothesis was that the isomerase gene is more likely to be up-regulated in GFFD cells 
compared to MCC, and the RNA sequencing data may be considered together with the LC-MS 
protein data for identifying isomerase candidates.  
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A preliminary experiment was conducted to confirm the location of GFFD cells and determine 
the sample size for RNA sequencing. Neurons from a region in the pedal ganglion between pedal 
nerve 7 (P7) and pedal nerve 9 (P9) were isolated and analyzed directly by matrix-assisted laser 
desorption ionization (MALDI) mass spectrometry to determine if they contain the GFFD-
related peptides. Fig 6-7 shows the location of neurons (circled in white) that were found to 
contain GFFD and their representative mass profile, and this cluster of 5-7 cells was dissected 
from the left and right pedal ganglion for RNA sequencing. There are two MCC neurons in each 
animal, which can be easily identified based on location and size [21]. Approximately 30 ng of 
RNA was extracted from two MCC cells in an animal, and ~40 ng of RNA was extracted from 
the two GFFD cell clusters in one animal. Based on this, we decided to pool RNA material from 
four animals per replicate, and three replicates were included for each cell type for RNA 
sequencing.   
RNAseq libraries were prepared from MCC and GFFD cells and sequenced on one lane with 
reads 150 nt in length, resulting in around 35 million reads that aligned uniquely within the 
21,035 genes in NCBI’s Aplysia californica Annotation Release 101. The percentage of original 
reads that ended up aligning uniquely within these genes’ exons ranged from 52% to 67%. 
Among the uniquely aligned genes, 8,304 genes did not have logCPM > log2(0.5) in at least 
three samples and were filtered out, leaving 12,731 genes to be analyzed for differential 
expression. Principle component analysis clustering of the samples (Fig. 6-8) indicated one of 
the MCC replicates was more variable than the other two. Rather than remove this sample 
completely, we did a surrogate variables analysis [23,24] on the logCPM values, which estimated 
one surrogate variable accounting for the difference in this replicate. We identified 519 genes 
(with false discovery rate (FDR)-adjusted p-value < 0.05) that were differentially expressed 
134 
 
between the two cell types. Fig. 6-9A plots the fold change against the average expression level 
for all 12,731 genes, using MCC as the baseline group. Genes that are up-regulated (242 genes, 
FDR p < 0.05) in GFFD cells compared to MCC are shown in red, and genes that are down-
regulated (277 genes, FDR p < 0.05) are shown in blue. Fig. 6-9B shows individual expression 
values for one of the genes with the highest expression level and the highest fold-change 
difference between the two cell types, namely the achatin-like neuropeptide precursor. This is 
notable because the achatin-like neuropeptide precursor is the protein that is processed into 
GFFD-related DAACPs, which is the basis of selecting the GFFD cell type. 
6.3.4 Isomerase candidates  
In the RNA sequencing experiment, 242 genes were found to be up-regulated in the DAACP-
expressing GFFD cells. This list of genes was search against the LC-MS data from protein 
purification experiments. Based on both gene expression data from RNA sequencing and LC-MS 
protein data from enzyme purification, we identified 11 proteins as candidates for the isomerase 
(Table 6-3). Gene ontology (GO) terms for molecular function for these protein sequences were 
predicted using the PredictProtein server, which searches up-to-date public sequences databases 
to create alignments and predict aspects of protein structure and function [25]. Six proteins were 
predicted to have catalytic functions and three proteins had predicted GO terms for binding 
(Table 6-4). The sequences of these isomerase candidates are shown in Table 6-5. 
 
6.4 Conclusion and Future Directions  
In summary, an L/D-peptide isomerase was partially purified from the central nervous system of 
Aplysia californica. Potential protein sequences for this enzyme were identified based on LC-
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MS/MS protein analysis of active isomerase fractions as well as differential gene expression 
analysis of two neuronal cell types (DAACP-expressing cells vs. control). To confirm the 
sequence of this novel enzyme, we are currently focused on expressing the isomerase candidates 
in bacterial, yeast, and mammalian expression systems. The DNA sequences of open-reading 
frames (ORFs) encoding each isomerase candidate were obtained through NCBI Gene records. 
N-terminal signal peptide sequences were predicted using the SignalP 4.1 server [19,20] and 
removed, and the modified ORF sequences were chemically synthesized. Protein expression 
experiments are ongoing, and expressed isomerase candidates will be assayed to determine if 








Figure 6-1. ANX ion exchange chromatography. The column was a HiTrap ANX FF (high sub) 
column; the buffer was 20 mM Bis-Tris with 5 mM EDTA, pH 7. Black trace: absorbance at 280 












































Figure 6-2. MRM chromatograms showing the isomerase activity in each ANX fraction. GFFD 
was incubated with each protein fraction at 37 °C for 24 h. Formation of GdFFD (arrow) was 
only detected in the fraction eluted with 0.5 M NaCl. 
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Figure 6-3. Isomerase purification using hydrophobic interaction chromatography. Black trace: 
absorbance at 280 nm. The column was a Phenyl-Superose HR 5/5 column; the buffer was 25 
mM Tris-HCl with 5 mM EDTA, pH 8.3. Blue trace: ammonium sulfate gradient from 1 M to 0 












































Figure 6-4. Isomerase purification using size exclusion chromatography. The column was a 
Superose-12 10/300 GL column; the buffer was PBS. Black trace: absorbance at 280 nm. Green 








































Figure 6-5. MRM chromatograms showing the isomerase activity of ANX-HIC-SEC fractions 
that were selected for LC-MS/MS protein analysis. The L-form substrate GFFD was incubated 
















Figure 6-6. Summary of LC-MS/MS protein data analysis. 
  

























Figure 6-7. MALDI-TOF MS analysis of pedal neurons. Top left: left pedal ganglion. Top right: 
right pedal ganglion. Cells in the area circled in white were found to contain GFFD-related 
peptides. Bottom: representative mass spectrum of a GFFD-containing cell. GFFD-related 



































Figure 6-8. Principle component analysis clustering of the samples before (left) and after (right) 
surrogate variable correction.  Surrogate variable analysis was performed to correct for variation 
in the samples not due to neuron type. After surrogate variable correction, the variation in MCC 







Figure 6-9. Differential gene expression of GFFD cells vs. MCC. A. The average expression 
(units are TMM-normalized counts per million reads in log2 scale) was plotted against the fold 
change (log2 scale). Each point is a gene, red represents up-regulated genes and blue represents 
down-regulated genes with FDR p < 0.05. B. Expression level of the achatin-like neuropeptide 
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Table 6-1. Summary of enzyme purifications 



































HIC  SEC 
 
+ + 






ANX HIC SEC + + + 
 
a
 S: ion exchange Mono S HR 5/5 column 
b
 Q: ion exchange MonoQ HR 5/5 column 
c
 SEC: size exchange Superose-12 10/300 GL column 
d
 HIC: hydrophobic interaction Phenyl-Superose HR 5/5 column 
e
 S-Q: protein sample was passed through S; the flow-through from S was passed over Q 
f
 ANX: HiTrap ANX FF (high sub) column  
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Column Type Charged group pH Flow-through Wash Elution 
SP strong cation -CH2CH2CH2SO3
-
 
pH 5 + 
 
+ 
pH 6 + + + + + + 
pH 7 + + + + 
 
CM weak cation -O-CH2COO
-
 
pH 5 + 
 
+ 
pH 6 + + + + + + 
pH 7 + + + 
 










   










   












   
147 
 
Table 6-3. Protein candidates for the Aplysia L/D-peptide isomerase 
a
 up-regulated gene in GFFD cells compared to MCC 
b
 P1: three stage ANX-HIC-SEC purification 
c
 P2: three stage ANX-HIC-SEC purification 
d













1 XP_005103216.2 41324 PREDICTED: uncharacterized protein LOC101863915 101863915 v v v 
 
2 XP_012935925.1 17486 PREDICTED: uncharacterized protein LOC106011308 106011308 v  v  
3 XP_005094765.2 35818 PREDICTED: UPF0764 protein C16orf89 homolog 101846868 v v  v 
4 XP_005105496.1 22597 PREDICTED: uncharacterized protein LOC101855585  101855585  v v v 
5 XP_005090553.1 21610 PREDICTED: peptidyl-prolyl cis-trans isomerase 6-like 101849343  v v v 
6 XP_005106031.1 18296 PREDICTED: uncharacterized protein LOC101859590 101859590  v v v 
7 XP_005097640.1 17082 PREDICTED: uncharacterized protein LOC101860016 isoform X1 101860016  v v  
8 XP_005096779.1 19514 PREDICTED: uncharacterized protein LOC101856886  101856886  v v v 
9 XP_005098882.2 36604 PREDICTED: carbonic anhydrase 2-like 101847875  v v v 
10 XP_012934586.1 24770 PREDICTED: laminin subunit alpha-like 106011018  v v v 
11 XP_005094514.2 42639 PREDICTED: probable peptidyl-alpha-hydroxyglycine alpha-
amidating lyase F21F3.1 
101849446  v v v 
148 
 











* gene ontology term for molecular function 
 
 
# Protein ID GO term* Reliability % Disulfide bridges 
1 XP_005103216.2 Binding 20 0 
2 XP_012935925.1 Catalytic 17 0 
3 XP_005094765.2 N/A - 3 
4 XP_005105496.1 Transferase 26 0 
5 XP_005090553.1 Cis/trans isomerase 45 0 
6 XP_005106031.1 Transporter 26 0 
7 XP_005097640.1 Oxidoreductase 20 0 
8 XP_005096779.1 N/A - 2 
9 XP_005098882.2 Lyase 42 0 
10 XP_012934586.1 Binding 32 0 
11 XP_005094514.2 Catalytic 32 0 
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Table 6-5. Protein sequences for isomerase candidates 






























































1. Kreil G (1997) D-amino acids in animal peptides. Annu Rev Biochem 66:337-345. 
doi:10.1146/annurev.biochem.66.1.337 
 
2. Mor A, Amiche M, Nicolas P (1992) Enter a new post-translational modification: D-amino 
acids in gene-encoded peptides. Trends Biochem Sci 17 (12):481-485 
 
3. Bai L, Sheeley S, Sweedler JV (2009) Analysis of Endogenous D-Amino Acid-Containing 
Peptides in Metazoa. Bioanal Rev 1 (1):7-24. doi:10.1007/s12566-009-0001-2 
 
4. Shikata Y, Watanabe T, Teramoto T, Inoue A, Kawakami Y, Nishizawa Y, Katayama K, 
Kuwada M (1995) Isolation and characterization of a peptide isomerase from funnel web spider 
venom. J Biol Chem 270 (28):16719-16723 
 
5. Jilek A, Mollay C, Tippelt C, Grassi J, Mignogna G, Mullegger J, Sander V, Fehrer C, Barra 
D, Kreil G (2005) Biosynthesis of a D-amino acid in peptide linkage by an enzyme from frog 
skin secretions. Proc Natl Acad Sci U S A 102 (12):4235-4239. doi:0500789102  
 
6. Torres AM, Tsampazi M, Tsampazi C, Kennett EC, Belov K, Geraghty DP, Bansal PS, 
Alewood PF, Kuchel PW (2006) Mammalian l-to-d-amino-acid-residue isomerase from platypus 
venom. FEBS Lett 580 (6):1587-1591. doi:S0014-5793(06)00159-1  
 
7. Sheeley SA, Miao H, Ewing MA, Rubakhin SS, Sweedler JV (2005) Measuring D-amino acid-
containing neuropeptides with capillary electrophoresis. Analyst 130 (8):1198-1203. 
doi:10.1039/b504717j 
 
8. Bai L, Livnat I, Romanova EV, Alexeeva V, Yau PM, Vilim FS, Weiss KR, Jing J, Sweedler 
JV (2013) Characterization of GdFFD, a D-amino acid-containing neuropeptide that functions as 
an extrinsic modulator of the Aplysia feeding circuit. J Biol Chem 288 (46):32837-32851. 
doi:10.1074/jbc.M113.486670 M113.486670 
 
9. Livnat I, Tai HC, Jansson ET, Bai L, Romanova EV, Chen TT, Yu K, Chen SA, Zhang Y, 
Wang ZY, Liu DD, Weiss KR, Jing J, Sweedler JV (2016) A d-Amino Acid-Containing 
Neuropeptide Discovery Funnel. Anal Chem 88 (23):11868-11876. 
doi:10.1021/acs.analchem.6b03658 
 
10. Romanova EV, Annangudi SP, Tai H-C, Sweedler JV (2017) Mass Spectrometry of Proteins. 




11. McCormack AL, Schieltz DM, Goode B, Yang S, Barnes G, Drubin D, Yates JR (1997) 
Direct Analysis and Identification of Proteins in Mixtures by LC/MS/MS and Database 
Searching at the Low-Femtomole Level. Analytical Chemistry 69 (4):767-776. 
doi:10.1021/ac960799q 
 
12. Zhang Y, Fonslow BR, Shan B, Baek M-C, Yates JR (2013) Protein Analysis by 
Shotgun/Bottom-up Proteomics. Chemical Reviews 113 (4):2343-2394. doi:10.1021/cr3003533 
 
13. Team RC (2017) R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria 
 
14. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, 
Gatto L, Girke T, Gottardo R, Hahne F, Hansen KD, Irizarry RA, Lawrence M, Love MI, 
MacDonald J, Obenchain V, Oles AK, Pages H, Reyes A, Shannon P, Smyth GK, Tenenbaum D, 
Waldron L, Morgan M (2015) Orchestrating high-throughput genomic analysis with 
Bioconductor. Nat Methods 12 (2):115-121. doi:10.1038/nmeth.3252  
 
15. Robinson MD, Oshlack A (2010) A scaling normalization method for differential expression 
analysis of RNA-seq data. Genome Biol 11 (3):R25. doi:10.1186/gb-2010-11-3-r25  
 
16. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data. Bioinformatics 26 (1):139-140. 
doi:10.1093/bioinformatics/btp616 
 
17. Lun AT, Chen Y, Smyth GK (2016) It's DE-licious: A Recipe for Differential Expression 
Analyses of RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR. Methods Mol 
Biol 1418:391-416. doi:10.1007/978-1-4939-3578-9_19 
 
18. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B 
(Methodological) 57 (1):289-300 
 
19. Petersen TN, Brunak S, von Heijne G, Nielsen H (2011) SignalP 4.0: discriminating signal 
peptides from transmembrane regions. Nat Methods 8 (10):785-786. doi:10.1038/nmeth.1701 
 
20. Nielsen H (2017) Predicting Secretory Proteins with SignalP. Methods Mol Biol 1611:59-73. 
doi:10.1007/978-1-4939-7015-5_6 
 
21. Moroz LL, Edwards JR, Puthanveettil SV, Kohn AB, Ha T, Heyland A, Knudsen B, Sahni A, 
Yu F, Liu L, Jezzini S, Lovell P, Iannucculli W, Chen M, Nguyen T, Sheng H, Shaw R, 
152 
 
Kalachikov S, Panchin YV, Farmerie W, Russo JJ, Ju J, Kandel ER (2006) Neuronal 
transcriptome of Aplysia: neuronal compartments and circuitry. Cell 127 (7):1453-1467. 
doi:S0092-8674(06)01595-9  
 
22. Romanova EV, Sasaki K, Alexeeva V, Vilim FS, Jing J, Richmond TA, Weiss KR, Sweedler 
JV (2012) Urotensin II in invertebrates: from structure to function in Aplysia californica. PLoS 
One 7 (11):e48764. doi:10.1371/journal.pone.0048764 PONE-D-12-17738  
 
23. Leek JT, Storey JD (2007) Capturing heterogeneity in gene expression studies by surrogate 
variable analysis. PLoS Genet 3 (9):1724-1735. doi:07-PLGE-RA-0237 
 
24. Leek JT, Storey JD (2008) A general framework for multiple testing dependence. Proc Natl 
Acad Sci U S A 105 (48):18718-18723. doi:10.1073/pnas.0808709105  
 
25. Yachdav G, Kloppmann E, Kajan L, Hecht M, Goldberg T, Hamp T, Honigschmid P, 
Schafferhans A, Roos M, Bernhofer M, Richter L, Ashkenazy H, Punta M, Schlessinger A, 
Bromberg Y, Schneider R, Vriend G, Sander C, Ben-Tal N, Rost B (2014) PredictProtein--an 
open resource for online prediction of protein structural and functional features. Nucleic Acids 







L/D-PEPTIDE ISOMERASE ACTIVITY IN RODENTS 
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7.1 Introduction 
L/D-peptide isomerization is a post-translational modification in which an L-amino acid residue 
in a peptide is enzymatically converted into a D-amino acid residue. Close to 40 endogenous D-
amino acid-containing peptides (DAACPs) have been discovered in animal species ranging from 
invertebrate animals such as mollusks and arthropods to vertebrates including amphibians and 
monotremes (platypus and echidna) [1,2]. In humans and rodent models, D-amino acid residues 
have been observed in peptides and proteins associated with aging-related disorders, and these D-
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residues are believed to result from spontaneous isomerization and accumulated throughout the 
life span [3]. In the scope of this study, the term DAACP refers to bioactive peptides that are 
formed as a result of post-translational modification by an enzyme and function as chemical 
messengers in cell-to-cell signaling. In this sense, the only known mammalian DAACPs are the 
monotreme venom peptides [4-6], and cell-cell signaling DAACPs have yet to be confirmed in 
humans, rodents, or other mammals due to analytical difficulties in their detection. 
Following the discovery of DAACPs in animals, the first eukaryotic enzyme that catalyzes the L-
to-D isomerization of an amino acid residue in a peptide chain was purified from spider venom 
and fully sequenced [7]. Almost a decade later, a frog isomerase was purified from frog skin 
secretions and partially sequenced [8]. Next, a platypus isomerase was isolated and partially 
characterized, but its sequence remains unknown to date [9]. Isomerase activity was also 
detected in the venom of the echidna, which is related to the platypus [6].  
Of particular interest is a study in which an all-L-form peptide substrate was converted into its 
DAACP isomer in tissue extracts from the mouse heart [10]. Since endogenous mouse DAACPs 
are not known, the two peptide substrates used in this study were synthesized based on the 
peptide substrate for the platypus isomerase. When the L-substrates were incubated in the heart 
extracts and analyzed with HPLC, a very small peak corresponding to the D-form product was 
detected post-incubation for both substrates. This study is notable for being the first time that 
L/D-peptide isomerase activity was reported in placental mammals. However, there have been no 
reports of follow-up studies on the mouse isomerase since then.     
In an ongoing study in our group, the Aplysia isomerase was partially purified and characterized 
from the central nervous system, and sequencing efforts are currently underway. In the present 
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study, we applied our isomerase assay development and purification strategy to investigating the 
L/D-peptide isomerase activity in rodents. We first repeated and confirmed the presence of 
isomerase activity in the mouse heart; we then established the presence of isomerase activity in 
rat tissues and identified the mammalian neuropeptide FF as a potential endogenous substrate for 
the rat isomerase.   
 
7.2 Experimental Procedures 
Materials. The peptides GFFD and GdFFD were synthesized by the Protein Sciences Facility of 
the Roy J. Carver Biotechnology Center at the University of Illinois at Urbana-Champaign; 
I(Nle)FdSdRdS, I(dNle)FdSdRdS, and FdLFPQRFa were synthesized by Genscript (Piscataway, 
NJ); and Neuropeptide FF (FLFPQRFa) was purchased from Genscript. LC-MS grade water, 
acetonitrile (ACN), and formic acid (FA) were purchased from Thermo Fisher Scientific 
(Waltham, MA). The Halt Protease Inhibitor Cocktail and T-PER Tissue Protein Extraction 
Reagent were purchased from Thermo Scientific. All other chemicals and reagents were 
purchased from Sigma-Aldrich (St. Louis, MO). 
Animals. Male Sprague-Dawley rats (1-3 months old) were obtained from Envigo (Indianapolis, 
IN). BALB/c mice (2-3 weeks old) of both sexes were used for the mouse heart experiments. 
Animal protocols were approved by the Institutional Animal Care and Use Committee at the 
University of Illinois at Urbana-Champaign. Dissected tissues were frozen immediately and 
stored at -80 °C until used. 
Enzyme preparation. Frozen tissue was reduced to a coarse powder in a stainless steel tissue 
pulverizer that was pre-chilled in liquid nitrogen. Ice-cold PBS with 5 mM 
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ethylenediaminetetracetic acid (EDTA) was added to the powder at a ratio of 10 mL extraction 
buffer per 1 g tissue, and homogenized on ice using a PowerGen 125 Homogenizer (Fisher 
Scientific) for 5 bursts of 5 s each. The homogenate was centrifuged at 12,500 x g for 20 min. 
After centrifugation, the solid material was discarded and the supernatant was filtered through a 
0.45 μm syringe filter. The filtrate was adjusted to a 1 M ammonium sulfate solution by drop 
wise addition of saturated (4 M) ammonium sulfate, left on ice for 20 min, then centrifuged at 
12,500 x g for 10 min. A portion of the supernatant (containing ~ 5 mg total protein) was loaded 
onto a Phenyl-Superose HR 5/5 column (GE Healthcare Life Sciences, Marlborough, MA) on an 
AKTA fast protein liquid chromatography (FPLC) system (GE Healthcare Life Sciences) and 
fractionated at a flow rate of 0.5 mL/min. The buffer was 25 mM Tris-HCl pH 8.3 with 5 mM 
EDTA, and the gradient was 1 M to 0 M ammonium sulfate over 15 column volumes. 40 
fractions were collected at 0.5 mL/Fr, and each fraction was tested for isomerase activity.  
Isomerase assay. For each assay, 100 μL of enzyme sample was concentrated and exchanged 
into 30 μL of 50 mM phosphate buffer with 5 mM EDTA, pH 6 (standard assay buffer) using a 
Nanosep Centrifugal Device with the Omega 10 kDa MWCO membrane (Pall Corporation, Port 
Washington, NY). For assays where protease inhibitors were added, a 100x stock of the protease 
inhibitor was diluted into the standard assay buffer at 1x working concentration and used for 
buffer exchange. 2 μL of 0.1 mg/mL I(Nle)FdSdRdS peptide substrate and 2 μL of 5 μg/mL 
GFFD (as negative control) were added to the enzyme sample and incubated at 37 °C for 48 h 
unless otherwise stated. Samples were desalted and concentrated with solid-phase extraction 
using reversed-phase C18 ZipTip pipette tips (Millipore, Burlington, MA) prior to LC-MS 
analysis. Briefly, the sample was adjusted to 0.1% trifuoroacetic acid (TFA), pH < 4; the ZipTip 
was washed twice with 10 μL ACN and twice with 10 μL 0.1% TFA in water, then the sample 
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was loaded onto the resin by aspirating and dispensing the sample 10 times through the tip. The 
tip was then washed three times with 10 μL of 5% methanol in water with 0.1% TFA, to remove 
salts and unbound molecules. The purified peptide sample was eluted in 20 μL of 50% ACN in 
water with 0.1% FA. 
LC-MS/MS-MRM analysis. Isomerase assay samples were analyzed in the multiple reaction 
monitoring (MRM) mode on an LC-MS/MS system that consisted of an Advance ultra-high 
performance LC coupled to an EVOQ triple-quadrupole mass spectrometer (Bruker, Billerica, 
MA). The MS was operated with the following parameters: heated electrospray ionization (HESI) 
source, (±) spray voltage = 4000 V, cone temperature = 250 °C, cone gas flow = 20, heated 
probe temperature = 400 °C, probe gas flow= 45, and nebulizer gas flow = 50. The LC column 
was an XSelect CSH C18 3.5 μm column, 4.6 x 150 mm (Waters, Milford, MA), and the 
solvents were water with 0.1% FA (solvent A) and ACN with 0.1% FA (solvent B). The 15 min 
gradient was 5-15% B in 2 min, 15-30% B in 8 min, 30-70% B in 1 min, 70% B for 1 min, 70-
5% B in 1 min, and 5% B for 2 min, at a flow rate of 1 mL/min. 
Detergent removal. For experiments that used T-PER as the protein extraction buffer, an extra 
detergent removal step was performed on the crude protein extract since detergents interfere with 
downstream MS analysis. Pierce Detergent Removal Spin Columns (Thermo Scientific) were 
used to remove detergents from protein samples according to product instructions. Briefly, the 
spin column was centrifuged for 1 min at 1,500 x g to remove the storage buffer and then rinsed 
three times with 0.4 mL PBS. The detergent-containing protein sample was added to the column 
and incubated at room temperature for 10 min. After incubation, the column was centrifuged for 




7.3 Results and Discussion 
7.3.1 L/D-peptide isomerase activity in the mouse heart 
Protein extract from the mouse heart was fractionated using hydrophobic interaction 
chromatography, and each fraction was tested for peptide isomerase activity using the synthetic 
peptide I(Nle)FdSdRdS as the standard substrate (where Nle is norleucine and the lower case 
letter d denotes a D-amino acid). This hexapeptide was derived from DLP-4, which is an 
endogenous substrate of the platypus L/D-peptide isomerase, and was shown to be converted to 
I(dNle)FdSdRdS in mouse heart extracts by Koh et al. [10] where the second residue was 
isomerized into D-norleucine. Under our assay conditions, we were also able to show the 
conversion of the standard substrate into its D-norleucine-containing isomer in a fraction of the 
mouse heart protein extract (Fig. 7-1). The product could be separated from the substrate by 
reversed phase HPLC, the mass was confirmed by multiple-reaction-monitoring mass 
spectrometry, and the retention time was matched to the synthetic D-form peptide standard. 
7.3.2 L/D-peptide isomerase activity in rat tissues 
Once isomerase activity was confirmed in the mouse heart, we hypothesized that this enzyme 
activity should also be present in other mammalian species, including the rat. We therefore 
applied our enzyme isolation procedure and isomerase assay to testing for L/D-peptide isomerase 
activity in rat tissues. Besides the significance of establishing isomerase activity in another 
mammalian species, working with the rat is also advantageous in that it is easier to obtain more 
material for enzyme isolation.  
As a first step, PBS and a commercial tissue protein extraction reagent, T-PER (Thermo 
Scientific), were evaluated as buffers for the initial protein extraction from rat heart tissue. Both 
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buffers contained 5 mM EDTA and were tested with and without the addition of the Halt 
Protease Inhibitor Cocktail (Thermo Scientific). As shown in Fig. 7-2, isomerase activity was 
detected in both the PBS-extracted and T-PER-extracted protein sample. Although the level of 
the L-form substrate post-incubation was higher in the T-PER sample (indicating less 
degradation of the substrate), the D-form product was found at similar levels in both samples. 
Interestingly, addition of a protease inhibitor cocktail abolished the isomerase activity in both 
cases, suggesting that one or more component of the protease inhibitor cocktail may act as an 
inhibitor of the L/D-peptide isomerase. Since T-PER contained a detergent component which was 
incompatible with the downstream LC-MS analysis in our assay, protein extraction with T-PER 
required an additional step in which the detergent was removed using a spin column. To 
minimize enzyme loss through sample handling, PBS with 5 mM EDTA was selected as the 
extraction buffer for subsequent experiments.   
In addition to the heart, five regions from the rat central nervous system (cortex, hippocampus, 
cerebellum, brain stem, and spinal cord) as well as four other tissue types (lungs, liver, adrenal 
glands, and bladder) were screened for isomerase activity (Fig. 7-3). In these experiments, the 
same amount of material (based on tissue weight) was fractionated using hydrophobic interaction 
chromatography and subjected to the isomerase assay. Formation of the D-form peptide was 
detected at varying levels in the cortex, hippocampus and spinal cord, but was not detected in the 
brain stem or cerebellum. In the liver and adrenal glands, the results were inconclusive as neither 
the L-substrate nor the D-product was detected after incubation, this was likely due to 
protease/peptidase activity in the enzyme sample. The bladder was found to be negative for 
isomerase activity, and the lungs exhibited the highest activity of all regions tested.  
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These results can be compared to the study by Koh et al. [10] looking at L/D-peptide isomerase 
activity in the mouse, where the authors tested eight mouse tissues including the brain, heart, 
kidney, liver, lung, small intestine, spleen, and stomach. In their experiments, the mouse tissue 
extracts were fractionated by centrifugal ultrafiltration and the assay samples were analyzed by 
HPLC. Peptide isomerization was only detected in the mouse heart but not in any of the other 
tissues, possibly due to degradation of the peptide substrate. We made significant improvements 
to this method by employing FPLC for protein fractionation and utilizing a highly sensitive LC-
MS/MS-MRM system for peptide detection. Our results showed that L/D-peptide isomerase 
activity was present in multiple tissues in the rat, which implies that peptide isomerization may 
be a widespread occurrence and underlines the functional importance of enzymatically derived 
D-amino acid-containing peptides. 
7.3.3 Inhibition of rat isomerase activity 
Based on results of the tissue screening experiment, peptide isomerization in the rat lungs was 
further investigated as a starting point for identifying and characterizing the rat L/D-peptide 
isomerase. Protein extracts were prepared separately from the lungs of three animals, isomerizing 
activity was confirmed in each animal, and the active fractions were pooled for subsequent 
experiments. As shown in Fig. 7-4, conversion of the L-form substrate into the D-form product 
was not observed if the tissue protein fraction was heated in boiling water for 10 min prior to 
incubation with the substrate, or if a protease inhibitor cocktail (Halt Protease Inhibitor Cocktail, 
Thermo Scientific) was added to the reaction buffer (as shown previously for rat heart extracts). 
Both results support the claim that peptide isomerization was the result of an enzyme that was 
susceptible to heat inactivation and chemical inhibition. The D-form peptide was not observed 
when the L-form substrate was incubated in a buffer control (without the extracted protein 
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fraction), indicating that spontaneously isomerization did not occur under the assay conditions. 
No peaks were detected for either the L- or D-peptide isomer when the tissue protein fraction was 
incubated by itself (without addition of the peptide substrate), showing that there were no 
endogenous peptides or protein degradation fragments that would interfere with the analysis. 
Next, individual components (AEBSF, aprotinin, bestatin, E-64, and leupeptin) from the protease 
inhibitor cocktail were tested in order to identify the inhibitor(s) that were responsible for the 
inhibition effect. Of the five inhibitors tested, only AEBSF was found to inhibit isomerase 
activity in the rat lungs (Fig. 7-5). AEBSF (or 4-(2-aminoethyl)benzenesulfonyl fluoride) is an 
irreversible serine protease inhibitor that reacts with the hydroxyl group of an active site serine 
residue to form a sulfonyl enzyme derivative [11]. Based on our results, it is likely that the active 
site of the rat isomerase contains a catalytic serine (or threonine) residue [12]. It is interesting to 
note that the isomerase from the Aplysia nervous system also exhibited sensitivity to AEBSF, 
and it is possible that the two enzymes share similarities in their active site and/or reaction 
mechanism. 
7.3.4 Conversion of neuropeptide FF  
Mammalian neuropeptide FF (FLFQPQRFa) is an FMRFamide-related peptide that has been 
implicated in a variety of physiological functions including the control of pain and analgesia 
through interactions with the opioid system [13-15]. There are several reasons to suspect that 
neuropeptide FF may exist as a D-amino acid-containing peptide (DAACP) in mammals. Firstly, 
another peptide from the FMRFamide-related peptide family, Mytilus-FFRFamide 
(AdLAGDHFFRFa), contains a D-leucine in the second position and is known to be an 
endogenous and bioactive DAACP in the bivalve mollusk Mytilus edulis [16]. In a study on the 
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substrate specificity of the frog L/D-peptide isomerase, neuropeptide FF was identified as a 
potential substrate in a database search, based on its N-terminal sequence matching to the 
consensus sequence for the frog enzyme [17]. When tested, neuropeptide FF was indeed found to 
be isomerized by the frog isomerase. In our rodent isomerase assays, since there are no 
confirmed DAACPs in the mouse or rat and endogenous substrates are not known, the peptide 
I(Nle)FdSdRdS (derived from the platypus substrate and used in the original mouse heart study 
[10]) was used as the standard substrate. Previous studies have shown that substrate specificity 
for both the frog and platypus isomerase is determined by the first three amino acid residues 
[17,18], and it was noted that the N-terminal sequence of I(Nle)FdSdRdS was similar to 
neuropeptide FF. Therefore, we hypothesized that neuropeptide FF could also be a substrate for 
the rat isomerase and tested it using enzyme fractions from the rat lungs.  
Fig. 7-6 compares the isomerase assay results for three peptide substrates. Isomerization of the 
standard, platypus-derived peptide I(Nle)FdSdRdS into I(dNle)FdSdRdS was observed as 
expected; isomerization of the Aplysia peptide GFFD was not observed; and the rat peptide 
FLFQPQRFa (neuropeptide FF) was isomerized into FdLFQPQRFa. This suggests that the rat 
isomerase is selective for specific residues at the second position- the hydrophobic residues 
leucine and norleucine were isomerized while the aromatic phenylalanine was not. It appears that 
the specificity of the rat isomerase is more similar to the platypus (where endogenous DAACPs 
contain the hydrophobic residues D-Leu and D-Met [4,5]) and the frog (where endogenous 
DAACPs contain D-Ala, D-Leu, D-Met, and D-alloisoleucine [19-24]). This is in contrast to the 
Aplysia isomerase, which seems to be specific for aromatic amino acid residues, and the spider 
isomerase which acted on a Ser residue [25,26]. The finding that neuropeptide FF can be 
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isomerized by rat tissue extracts is particularly exciting because it aids in both identifying the 
isomerase and in discovering novel mammalian DAACPs. 
 
7.4 Conclusion and Future Directions  
In this study we showed L/D-peptide isomerase activity in rat tissues that converted the second L-
amino acid residue of peptides into D-amino acid residues. This activity was found in the central 
nervous system as well as the heart and lungs, implying a broad distribution of the enzyme(s) 
and their DAACP products. A synthetic version of neuropeptide FF was found to be isomerized 
by the isomerase-active fraction, therefore it is possible that endogenous neuropeptide FF is also 
acted upon by an isomerase and exist as a DAACP.  
Future directions for this project include identifying the isomerase sequence, evaluating its 
expression and localization, and looking for homologs of the isomerase in other animals, 
including humans. The isomerase assay we developed here can also support the ongoing search 
for novel mammalian DAACPs. Various rat peptides can be tested as substrates for the 
isomerase, and those that are isomerized can be considered as potential DAACPs for further 
investigation. In the case of neuropeptide FF, the endogenous peptide will be isolated and the 
chirality of its amino acid residues will be assessed to determine if D-amino acids are present. If 
neuropeptide FF is confirmed as an endogenous DAACP, it would be the first enzymatically-
derived mammalian neuropeptide that contains a D-amino acid residue. These studies bring us 
another step forward in elucidating the extent and functional importance of L-to-D peptide 
isomerization in mammals and contribute to the understanding of the modifications and 
regulation of cell-to-cell signaling peptides.  
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7.5 Figures  
 
       
 
Figure 7-1. Isomerase activity in the mouse heart. Brown trace: MRM chromatogram showing 
the retention times of synthetic I(Nle)FdSdRdS (L) and I(dNle)FdSdRdS (D). Green trace: the L-
substrate was incubated with an enzyme fraction under conditions. The arrow points to formation 
of the D-product. Red trace: a control sample of the L-substrate incubated in buffer, showing that 
spontaneous isomerization did not occur under the assay conditions. 
 
  









Figure 7-2. Extraction conditions for isomerase activity in the rat heart. The L-substrate was 
incubated with rat heart tissue samples extracted using (1) PBS with 5 mM EDTA (green); (2) 
PBS, 5 mM EDTA plus 1x Halt Protease Inhibitor Cocktail (red); (3) T-PER with 5 mM EDTA 
(blue); (4) T-PER, 5 mM EDTA plus 1x Halt Protease Inhibitor Cocktail (magenta). Arrows 
point to formation of the D-product post-incubation. L: I(Nle)FdSdRdS, D: I(dNle)FdSdRdS. 
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Figure 7-3. Screening for isomerase activity in rat tissues. Ten tissue regions were tested for 
isomerase activity. Protein fractions prepared from each tissue were incubated with the standard 
L-substrate. After incubation, samples were analyzed with LC-MS/MS, and the MRM 
chromatograms are shown. Arrows point to peaks corresponding to the D-product (n=3 for lungs; 




















Figure 7-4. Isomerase activity in the rat lungs. Enzyme fractions were prepared from the rat 
lungs and incubated with the standard L-substrate. The D-product (indicated by the arrow) was 
detected under standard assay conditions (green), but isomerase activity was inhibited if a 
protease inhibitor cocktail was added (red) or if the enzyme fraction was heated in boiling water 
prior to incubation (blue). Two controls (brown, magenta) were also included.   

















Figure 7-5. Effect of protease inhibitors on the rat isomerase activity. Five compounds were 
tested for their ability to inhibit isomerase activity. Each compound was added to the assay 
buffer and incubated with the enzyme fraction and L-substrate. Samples post-incubation were 
analyzed with LC-MS/MS, and MRM chromatograms are shown with arrows pointing to peaks 
that correspond to the D-form product. 
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Figure 7-6. Isomerase activity on different substrates. Three peptides were evaluated as 
substrates for the rat isomerase. I(Nle)FdSdRdS (left panel) is the standard substrate, GFFD 
(middle panel) is an Aplysia peptide, and FLFQPQRFa (right panel) is mammalian neuropeptide 
FF. In each panel, the brown traces show the retention times of synthetic L- and D-form peptide 
standards; green traces represent control samples that did not contain the enzyme fraction; red 
traces represent each L-substrate incubated with the isomerase; and blue traces are control 
samples that only contained the enzyme fraction without addition of the L-substrate.    
  









Enzyme fraction only 
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8.1 Aplysia L/D-peptide isomerase 
Chapters 4-5 of this work described our efforts in detecting and partially characterizing a novel 
L/D-peptide isomerase activity in the central nervous system of Aplysia californica, but the 
sequence of this enzyme remains unknown. In Chapter 6, select protein sequences were 
identified as candidates for the isomerase, and the next step is to express these proteins and test 
for peptide isomerizing activity. While different expression systems offer different advantages, 
we opted to start with an E. coli expression system because of its rapid expression, high yield, 
and relative ease of handling. To prepare for protein expression, the DNA sequences of open-
reading frames (ORFs) for 11 isomerase candidates were obtained from the NCBI Gene database 
[1]. These ORF sequences were codon optimized for heterologous expression in E. coli, and the 
predicted signal peptide (predicted using the SignalP 4.1 server [2]) was removed from each 
sequence. The modified ORF sequences were chemically synthesized as gBlocks Gene 
Fragments (Integrated DNA Technologies, Inc., Coralville, IA) and then cloned into the pET-28a 
expression vector. Two out of the 11 protein candidates have been expressed in BL21(DE3) cells 
through isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced protein expression, and 
expression of the other isomerase protein candidates is currently underway. DNA construction 
and protein expression were carried out by Tong Si and Yuhao Min. 
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For expressed protein #1 (XP_005103216.2) and #2 (XP_012935925.1), both crude protein 
extracts and His-tag purified protein samples were assayed for isomerase activity. Initial 
results were inconclusive as there was substantial protease activity that interfered with the 
assay, and further studies are needed to optimize protein purification and sample preparation 
procedures. Another concern is that eukaryotic proteins expressed in bacteria may not be 
functional because bacterial cells cannot accomplish the required post-translational modifications 
(PTMs) or proper protein folding, and yeast or mammalian expression systems may need to be 
tested for better protein expression. Expressed protein candidates will be assayed to determine if 
they display L/D-peptide isomerase activity that matches the endogenous enzyme. In addition to 
identifying the sequence of the Aplysia isomerase, the ability to produce larger quantities of 
active enzyme will greatly facilitate the studies of enzyme kinetics, mechanism, structure, and 
other aspects of enzyme function. 
Once the sequence of the Aplysia isomerase is known, in situ hybridization or 
immunohistochemistry can be used to probe the localization and distribution of this enzyme in 
the nervous system. Since many Aplysia neurons can be uniquely recognized based on their 
morphology and location, it is possible to isolate specific cells that express the isomerase and 
investigate the occurrence of L/D-peptide isomerization at the single cell level, which can be 
advantageous for the discovery of novel D-amino acid-containing peptides (DAACPs). Likewise, 
knowing the identity of isomerase-containing and DAACP-expressing cells is helpful for 
establishing the function of newly discovered DAACPs, since the relationship between specific 
neurons and behavior is well-studied for certain neuronal circuits in Aplysia. Finally, a sequence 




8.2 Mammalian L/D-peptide isomerase 
Research into a mammalian L/D-peptide isomerase has been initiated in rodent tissues, as 
discussed in Chapter 7. Isomerase activity was observed in different rat tissues, most notably in 
the brain and lungs, and two peptide substrates were found to be isomerized into DAACPs when 
incubated with semi-purified enzyme fractions. The next steps for this project include confirming 
isomerase activity in individual brain regions and in other tissues by accumulating more repeats 
of isomerase purification experiments for each area, as well as testing additional rat peptides as 
possible substrates for the isomerase activity. Purification strategies for the rat isomerase should 
also be further developed to obtain greater quantities of purified enzyme for characterization 
studies and protein sequencing efforts. Considering the wealth of transcriptomic and proteomic 
data that are available on protein expression in specific brain regions in rodent models, it might 
be feasible to narrow down isomerase protein candidates based on the distribution pattern of the 
isomerase activity.   
Detection of isomerase activity in the rat lungs is intriguing because the lungs are well-known 
for producing antimicrobial peptides that are part of the innate immunity system. These peptides 
are secreted by epithelial and immune cells to act against respiratory bacteria, fungi, and viruses, 
and they are also involved in the modulation of immune responses to infections and injury [3,4]. 
Notably, the α- and β-defensins are a major family of antimicrobial peptides known to be 
expressed in the rat and human lungs [5-7], and in the platypus, a defensin-like peptide exists as 
a DAACP with D-Met in position 2 and is one of the only identified mammalian DAACPs to 
date [8]. One interesting speculation is that an L/D-peptide isomerase in the lungs is responsible 
for generating DAACPs that have antimicrobial activities; this aspect will be taken into account 
when analyzing the peptide substrates and functions for the lung isomerase. 
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8.3 Neuropeptide FF 
In Chapter 7, synthetic mammalian neuropeptide FF (amino acid sequence FLFQPQRFa) was 
found to be converted into FdLFQPQRFa when incubated in an isomerase-active fraction 
prepared from rat lungs, and it was hypothesized that endogenous neuropeptide FF could be 
present as a DAACP. Neuropeptide FF is encoded by the Npff gene, which is broadly expressed 
in the tissues of rat, human, and other mammals (NCBI Gene [1]). In a rat RNA-seq 
transcriptomics study cataloguing the gene expression profile in 11 organs and 4 developmental 
stages, Npff was expressed in all organs tested, with the highest expression level found in the 
lungs [9]. It is therefore reasonable to speculate that neuropeptide FF could be an endogenous 
substrate of the isomerase activity in the rat lungs. This peptide has been implicated in wide-
ranging physiological actions including pain modulation, central cardiovascular regulation, 
hormonal control, and food intake [10-13], and it is likely to have other functions as well.  
To determine if endogenous neuropeptide FF exists as a DAACP in the rat, peptide mixtures 
extracted from multiple tissues will be analyzed with a sensitive multiple reaction monitoring 
(MRM) system, and the presence of the DAACP isomer (FdLFQPQRFa) can be distinguished 
from the all-L-form peptide isomer using reversed phase liquid chromatography, as shown in 
Chapter 7. If endogenous neuropeptide FF can be isolated, the chirality of its amino acid residues 
can be determined using the chiral analysis procedure described in Chapter 3. It is likely that 
multiple peptide extraction protocols will need to be tested for optimal extraction of 
neuropeptide FF, since this peptide was not detected in previous rat peptide characterizations 
using the standard protocol in our group. Detection of a D-amino acid-containing isomer of 
neuropeptide FF would be the first example of L/D-peptide isomerization as a PTM of cell-to-
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